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Abstract
The first consensus report of the working party of the Asian Pacific Association for the Study of the Liver (APASL) set up
in 2004 on acute-on-chronic liver failure (ACLF) was published in 2009. With international groups volunteering to join, the
“APASL ACLF Research Consortium (AARC)” was formed in 2012, which continued to collect prospective ACLF patient
data. Based on the prospective data analysis of nearly 1400 patients, the AARC consensus was published in 2014. In the past
nearly four-and-a-half years, the AARC database has been enriched to about 5200 cases by major hepatology centers across
Asia. The data published during the interim period were carefully analyzed and areas of contention and new developments in
the field of ACLF were prioritized in a systematic manner. The AARC database was also approached for answering some of
the issues where published data were limited, such as liver failure grading, its impact on the ‘Golden Therapeutic Window’,
extrahepatic organ dysfunction and failure, development of sepsis, distinctive features of acute decompensation from ACLF
and pediatric ACLF and the issues were analyzed. These initiatives concluded in a two-day meeting in October 2018 at New
Delhi with finalization of the new AARC consensus. Only those statements, which were based on evidence using the Grade
System and were unanimously recommended, were accepted. Finalized statements were again circulated to all the experts
and subsequently presented at the AARC investigators meeting at the AASLD in November 2018. The suggestions from the
experts were used to revise and finalize the consensus. After detailed deliberations and data analysis, the original definition
of ACLF was found to withstand the test of time and be able to identify a homogenous group of patients presenting with liver
failure. New management options including the algorithms for the management of coagulation disorders, renal replacement
Extended author information available on the last page of the article
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therapy, sepsis, variceal bleed, antivirals and criteria for liver transplantation for ACLF patients were proposed. The final
consensus statements along with the relevant background information and areas requiring future studies are presented here.
Article Highlights
•
•
•
•
•
•
•
•

Updated on the basis of AARC data of >3300 cases enrolled into AARC registry prospectively
ACLF is distinct form Acute Decompensation of cirrhosis
Newer sections on DILI-ACLF, AIH-ACLF, PVT/HVOTO–ACLF
Reversibility of Chronic Liver Disease in ACLF
Portal and systemic hemodynamics and their relevance in ACLF
Acute Portal Hypertension and Variceal progression in ACLF
AARC score as a guide for treatment strategies in ACLF
ACLF in Children-first consensus on pediatric ACLF

Keywords Liver failure · Cirrhosis · Jaundice · AARC· Chronic liver disease · Alcoholic liver disease · ALF ·
Decompensation · Acute decompensation
Abbreviations
ACLF	Acute-on-chronic liver failure
DILI	drug-induced liver injury
CAM	Complimentary and alternative
medicine
HDS	Herbs, drugs and supplements
AD	Acute decompensation
AIH	Auto immune hepatitis
BCS	Budd–Chiari syndrome
PVT	Portal vein thrombosis
AVB	Acute variceal bleed
PICD	Paracentesis induced circulatory
dysfunction
RRT	Renal replacement therapy
LT	Liver transplant
SOFA	Sequential organ failure assessment
qSOFA	Quick sequential organ failure
assessment
CANONIC-CLIF	Acute-oN-ChrONic LIver Failure in
Cirrhosis
CLIF	Chronic Liver Failure Consortium
MELD	Model end-stage liver disease
TPPM	Tongji prognostic predictor model

Introduction
Liver failure is a common medical ailment and its incidence
is increasing with the use of alcohol and growing epidemic
of obesity and diabetes. It can present as acute liver failure
(ALF) (in the absence of any pre-existing liver disease),
acute-on chronic liver failure (ACLF) (an acute deterioration of known or unknown chronic liver disease), or an acute
decompensation of an end-stage liver disease [1, 2]. Each
of these is a well-defined disease entity with a homogenous
population of patients with expected outcomes. Due to an
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overlap and lack of clarity of definitions and outcomes, entities like late-onset liver failure, sub-acute hepatic failure,
have become less relevant and there is lack of further publications suggesting removal of such terminologies to avoid
confusion [1, 2].
The growing interest in ACLF after the first consensus
definition of ACLF from APASL [2] is evident by the fact
that more than > 450 publications as full papers have been
published from the West (2) and the East and the trend is
increasing. The group of investigators working on liver failure in the Asia–Pacific region working for the past decade
carefully analyzed the patient characteristics, natural history
and outcome of such patients. The group met on yearly basis
and collated data on website (www.aclf.in). With the setting
up of the APASL ACLF Research Consortium (AARC) in
2012, the collaborative research work, publications and protocol driven unified treatment had gained momentum. The
retrospective and prospective data of patients from different
centers were analyzed, and the completed patient records
were utilized for defining predictors of mortality and grades
of liver failure and incidence of other organ failures [3].
The APASL ACLF consensus of 2014 was based on
about 1363 patients from 14 countries. During the past
nearly four and a half years (2014–2018), 5228 patients of
43 Centers from 15 countries have so far been registered in
the AARC database. These patients have been prospectively
enrolled and followed and form the basis of the new structured consensus.
Experts from across the world, especially from the
Asia–Pacific region, were requested to identify pertinent and
contentious issues in ACLF. After a round of deliberations,
8 major issues were identified for update. Further, data from
the AARC database were taken and analyzed and circulated
to all the participants.
The process for the development of the recommendations
and guidelines included: review of all available published
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literature on ACLF by individual and group of experts;
preparation of a review manuscript and consensus statements based on GRADE SYSTEM (Table 1) of evidencebased approach [4], circulation of consensus statements to
all experts, a survey of the current approaches for the diagnosis and management of ACLF; discussion on contentious
issues; and deliberations to prepare the consensus statement
by the experts of the working party. A 2-day meeting was
held on October 1–2, 2018, at New Delhi, India, to discuss
and finalize the consensus statements, recommendations
and guidelines. The finalized statements were circulated to
all the experts and subsequently finalized. These consensus statements and recommendations for the diagnosis and
management of ACLF are included in this review. A brief
background is included providing the available data and published information on each of the issues. Statements from the
previous consensus have been reproduced at places to give a
background and continuity.

The concept of ACLF and hepatic reserve
Acute liver failure is a well-defined medical emergency
which is defined as a severe liver injury, leading to coagulation abnormality usually with an INR ≥ 1.5, and any degree
of mental alteration (encephalopathy) in a patient without
pre-existing liver disease and with an illness of up to 4 weeks
duration [5].A proportion of patients who present with features mimicking ALF, however, have an underlying chronic
liver disease or cirrhosis of the liver. These patients grouped
together as acute-on-chronic liver failure (ACLF) also have
a poor outcome. These patients are distinctly different from
a group of cirrhotic patients who are already decompensated
[6] and have a sudden worsening of their condition, i.e.,
acute decompensation (AD) due to an acute event that may
present with hepatic or non-hepatic failure [6].
ACLF is a clinical syndrome manifesting as acute and
severe hepatic derangements resulting from varied insults.
This term was first used in 1995 to describe a condition in
which two insults to liver operate simultaneously, one of
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them being ongoing and chronic and the other acute [7].
Over the years, several definitions have been proposed, creating confusion in the field [8]. The time frame for the development of liver failure and ACLF has been several times
changed from 12 to 4 weeks again to 12 weeks [9]. Moreover, the nature of insult and the stage of underlying disease
have been variably used.
In fact, any patient who has an underlying chronic liver
disease with superimposed acute insult is labeled as having ACLF, irrespective of evidence of liver failure per se or
evidence of pre-existing cirrhotic decompensation. Several
investigators were concerned that this would lead to substantial overlap with decompensated liver disease. The main
emphasis of the fourth consensus meeting of the APASL
Working Party was to identify from this large group of
patients, a subset of patients who have a relatively homogenous presentation and potentially similar outcome and
restrict the use of the term ‘‘acute-on-chronic liver failure’’
to this subset. The 2009 APASL definition had provided a
basis to select patients presenting with a distinct syndrome.
To cover the entire spectrum of these patients, from mild
to most severe, patients with chronic liver disease with or
without cirrhosis of the liver were included and carefully
analyzed. It is understandable, though not well defined, that
the nature and degree of acute insult and the status of the
underlying chronic liver disease would determine the outcome in a patient (Fig. 1).
To give clarity to the primary event, a hepatic insult,
jaundice and coagulopathy, which defined liver failure, was
considered essential. In acute liver failure, though hepatic
encephalopathy (HE) is part of the definition, it follows liver
failure. Should one wait for defining the outcome of ‘acute
liver failure’ till the time extrahepatic organ failures set in or
not, remains contentious. For definition, the event must be
universally present in all patients. From the point of view of
intensivists, it is well known that with increasing number of
organ dysfunction or failure, the mortality would cumulatively increase. Undoubtedly, these events are predictive of
the outcome, the basis of SOFA score [10]. It is, therefore,

Table 1  Evidence grade used for the APASL Guidelines Adopted from Atkins et al. [4]
Grading of evidence
High quality
Moderate quality

Notes

Symbol

Further research is very unlikely to change our confidence in the estimate effect
Further research is likely to have an important impact on our confidence in the estimate of effect
and may change the estimate effect
Low or very low quality
Further research is very likely to have an important impact on our confidence in the estimate of
effect and may change the estimate effect. Any estimate of effect is uncertain
Grading of recommendations
Notes
Strong recommendation warranted Factors influencing the strength of the recommendation included the quality of the evidence,
presumed patient-important outcomes, and cost
Weaker recommendation
Variability in preferences and values, or more uncertainty: more likely a weak recommendation is
warranted. Recommendation is made with less certainty: higher cost or resource consumption

A
B
C
Symbol
1
2
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Fig. 1  Concept of ACLF and
the cohorts included in different
definitions. The figure describes
the response of the liver to an
acute hepatic injury, depending on the underlying hepatic
injury, prior decompensation,
time frame from insult to presentation with decompensation
and reversibility with mitigation
of the acute insult. The spectrum extends from acute liver
failure, acute-on-chronic liver
failure, acute decompensation,
end-stage liver disease. ACLF
is distinct like ALF when the
APASL definition is considered.
APASL definition is simple and
homogenous and is distinct

not surprising; the same has been reported in the Western
studies [11]. However, should organ failure be included in
defining the clinical syndrome of liver failure needs a thorough analysis. As a corollary, despite decades of extensive
experience, renal or circulatory dysfunction has not been
included in the definition of ALF. The issue whether sepsis
per se could lead to liver failure or is a result of liver failure
had been debated for many years and was again revisited.
However, sepsis is an integral part of development of multiorgan failure in any patient, be it of renal, pancreatic or cardiac origin.
In essence, ACLF is a distinct entity where acute hepatic
decompensation occurs in an established chronic liver disease or cirrhosis patient on exposure to acute insult in a
defined time frame resulting in a high short-term mortality.
Based on the data, attempts were made if the current definition of ACLF could be improved further (Table 2). Five
aspects were worked upon:
(1) The time frame for the acute insult in the initial (2009)
and subsequent definition of ACLF, the time for development of ascites and/HE after appearance of jaundice
and coagulopathy was kept as 4 weeks (28 days) [1, 2].
A mortality rate of more than 33% at 4 weeks was considered to be significant allowing recovery to less than
two-third of the patients in the 2014 consensus. The
additional new data after the previous consensus were
carefully analyzed and it showed a 4-week mortality of
around 39.9% [2]. Therefore, the definition of 4 week
for acute insult in ACLF was considered as appropriate
and was maintained.
2. Reversibility of the ACLF syndrome this is a feature of
the ACLF defined by the AARC criteria, as nearly all the
patients included are after the index presentation. With
mitigation of acute insult and over time, the hepatic
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reserve improves, fibrosis regresses and the portal pressure decreases. It was decided to define reversibility as
reversal of key components that were used for defining
the syndrome of liver failure, i.e., decrease of bilirubin
below 5 mg/dL and reversal of coagulopathy to INR
below 1.5 and no encephalopathy with or without resolution of ascites. It was interesting to find in the large
AARC database, of the 1844 patients with complete data
until day 90. About 70% of the survivors beyond day 90,
showed reversibility and they maintained this status for
a period of at least 1 year. Further, unlike patients with
decompensated cirrhosis and similar to patients with
ALF, the reversal of coagulopathy preceded the reversal
of jaundice, i.e., median time to reversal of coagulopathy
was 7 (4–30) days versus 19 (7–60) days for jaundice,
respectively. The median time to reversal of syndrome,
i.e., jaundice and coagulopathy, was 30 days. Baseline
albumin, AARC score and transient elastography predicted long-term reversibility in the recently analyzed
AARC data.
3. Recording ‘Index ‘or first presentation in the definition
of ACLF this issue was deliberated so as to define and
include a homogenous cohort of patients. The consideration of prior decompensation with recent worsening (difficult to differentiate from acute decompensation, AD)
or recovery from ACLF and followed by subsequent
presentation as ACLF (i.e., ‘ACLF again’) will lead to
confusion. It is important to distinguish the syndrome
of ACLF from other forms of liver failure, such as acute
decompensation and end-stage liver disease (ESLD).
There was a consensus to initiate prospective studies
comparing patient manifesting with index presentation,
prior decompensation or recent worsening of decompensated cirrhosis patients.

Pediatric cohort
Therapy
Reversibility of ACLF
syndrome

Golden window

Disease severity score

Time frame
Acute insult
Sepsis
Organ failure

Homogeneity

Exclusion Criteria

Diagnosis

Inclusion

Study cohort

Definition

NASCELD

Prospectively studied in 507 patients
Cirrhosis only
Compensated or decompensated
Two extrahepatic organ failure
Presentation not necessarily be liver failure
Can be repeated episodes of ACLF

Prospectively studied in 1343 patients
Cirrhosis only
Compensated or decompensated
Renal failure is mandatory (not liver failure for defining ACLF)
Presentation not necessarily be liver failure
Can be repeated episodes ACLF
Too late, reversibility is unlikely and thus may not
affect outcome
HCC

A syndrome characterized
An acute deterioration of pre-existing chronic liver
by acute deterioration in a patient of cirrhosis due to
disease usually related to a precipitating event and
infection presenting with two or more extrahepatic
associated with increased mortality at 3 months due
organ failure.
to multisystem organ failure

EASL/CLIF

Too late, reversibility is unlikely and thus may not
affect outcome
Patients who had infections but did not require hospital
admission.
Cirrhosis without infection.
Immune-compromised patients with human immunodeficiency virus (HIV) infection, prior organ transplant,
and disseminated malignancies
No. Any presentation, with prior decompensation or
Yes. Index presentation, previously unknown or com- No. Any presentation, with prior decompensation or
recent worsening of ongoing decompensation, acute
recent worsening of ongoing decompensation, acute
pensated, acute hepatic insult leading to liver failure
insult is not directed to liver in particular
insult is not directed to liver, in particular (40% are
as the driver.
of unknown acute insult), not liver but extrahepatic Any extrahepatic organic failure
organ failure, i.e., renal failure is must, systemic
inflammation but not the liver as driver.
4 weeks
4–12 weeks (variable)
Not defined
Hepatic
Hepatic or Systemic (extrahepatic)
Infection, i.e., systemic (extrahepatic)
Consequence/complication
Cause/precipitant
Cause/precipitant
Liver is primary to start with
Systemic inflammation leading to kidney failure as
Systemic inflammation leading to extrahepatic organic
Others subsequently
the primary with or without other organ failure
failure
AARC Score-prospective as well as validated
CLIF-C SOFA, Prospective but only expert opinion
MELD
CLIF-C SOFA
Well defined for therapy, i.e., by 7 days SIRS or sepsis No such
No such
as well as for decision regarding Liver Transplant
Yes
None
None
Regenerative and bridging therapy with good result
No such
No such
Yes
Not described
Not described

Early, reversibility is likely and thus may affect
outcome
Prior decompensation
HCC

Acute hepatic insult manifesting as jaundice and
coagulopathy
Complicated within 4 weeks by ascites and/or
encephalopathy in a patient with previously diagnosed or undiagnosed chronic liver disease associated with high mortality.
First consensus was the expert opinion, subsequently
prospectively evaluated in 1402 patient, subsequently in 3300 patients.
Compensated Cirrhosis (diagnosed or non-diagnosed)
CLD but not cirrhosis
Acute insult directed to liver
Presentation with liver failure to start with
Index presentation

APASL

Table 2  Comparison of the existing ACLF definitions commonly accepted
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4. Inclusion of mortality in definition the mortality was
included in 2014 AARC consensus definition for identifying a set of patients who have high 28-day mortality
so as to prioritize them for admission, treatment and
liver transplantation. At present, the ACLF definition
both by the APASL and CLIF-EASL includes mortality.
The group of experts raised the concern that mortality
is generally not part of definition in disease conditions.
Other experts, however, disagreed to this. After due
deliberations, it was decided to keep the statement on
mortality, in the AARC-ACLF definition.
5. Inclusion of organ failure in definition the Western definitions of ACLF include organ failure in the definition.
This issue was debated extensively. The data from the
AARC database were also analyzed. It was reiterated
that organ failure other than liver should not be part
of the definition. Diagnosis of liver failure along with
kidney, circulatory and respiratory failure is generally
a late event and is often a result of the primary organ,
i.e., liver failure (jaundice, deranged coagulation and/or
HE). The experts felt that organ dysfunction rather than
organ failure should be the time for raising suspicion
and making diagnosis of ALCF rather than when organ
failure(s) has already developed. This approach would
help in prioritizing organ-specific interventions.
The AARC definition of ACLF is a simple bed-side tool
(requires history taking, physical examination and simple
laboratory parameters) and can be used by primary care givers. It enables a clinician to stratify a patient presenting with
liver failure for early referral, early intervention and, hence,
allows a better chance of reversibility as well as improved
survival. The earlier criteria for defining the nature of acute
insult were reiterated, i.e., the event must be new and acute
and its impact on the patient’s condition should be discernible as liver failure within a given time frame of 4 weeks
[1, 2].
Recommendations
1.0		 The concept of ACLF and hepatic reserve.
1.1		The 28- and 90-day mortality is high in ACLF
patients (A1).
1.2.		Among the survivors at day 90, the reversal of
ACLF syndrome was noted in nearly 70% cases
(C2).
1.3.		Almost two-third of the patients, who had reversal
of the ACLF syndrome by day 90, show a persistent
regression of the disease at 1 year (C2).
1.4.		Reversal of coagulopathy precedes the reversal of
jaundice (C2).
1.5.		The baseline AARC liver failure grade can identify
patients who are likely to reverse (C2).
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1.6.		A higher platelet count, lower leukocyte count and
the absence of HE are additional independent predictors of reversibility (C2).
1.7.		Transient elastography needs to be evaluated for
identifying the reversibility of ACLF syndrome at
baseline as well as at follow-up (C2).
1.8		Will inclusion of terminology of ‘First’ presentation
in definition improve clarity and homogeneity.
1.8.1.	Inclusion or exclusion of prior decompensation and
‘first’ presentation for the definition of ACLF needs
prospective studies [B2].
1.9.		Including organ failure in definition- for utility or
futility?
1.9.1.	The terms “organ dysfunction” and “organ failure”
need to be described more clearly based on the
AARC database, used in APASL consensus [B2].
1.9.2.	Extrahepatic organ failure should not be included
in definition of ACLF, as this would lead to missing
out the potential therapeutic window for reversal of
the ACLF syndrome (A1).
1.9.3.	Liver failure for definition of ACLF should include
jaundice (serum bilirubin ≥ 5 mg/dL) and coagulation dysfunction (INR > 1.5) (A1).
1.10.		 Whether mortality should be part of definition?
1.10.1.	Mortality should not be part of the definition of
ACLF. One need not die to fulfill the criteria of
ACLF definition. Mortality is not generally part of
any definition in disease conditions (C2). However,
since the earlier (2014) definition had included
mortality, the same definition was agreed.

Definition of ACLF
There is no consistent definition of ACLF in the literature.
Each study done previously on ACLF has used its own
definition, and there is no unanimity in these definitions in
terms of criteria for liver failure, the acute event precipitating ACLF, and the diagnosis of underlying chronic liver
disease. Since most of these studies were on patients who
required liver support devices or liver transplantation, these
studies were biased toward including sicker patients in the
definition and patients having a mild disease were left out.
A detailed analysis of the definition of liver failure and
the need for the defined outcome of high 28-day mortality was taken into account. An estimated 33% mortality
at 28 days was considered important. Having analyzed
and defined the acute and chronic insults, the time frame
and the criteria of liver failure, development and course of
organ failure and sepsis, the APASL definition of ACLF
of 2009 was reassessed. It was reported that this definition
has been used in nearly 200 publications from the East and
the West and has been found to be simple to use and with a
high degree of predictive ability to define the outcome of a
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relatively homogenous group of liver failure patients with
underlying chronic liver disease.
The consensus definition is:
“ACLF is an acute hepatic insult manifesting as jaundice (serum bilirubin ≥ 5 mg/dL (85 micromol/L) and
coagulopathy (INR ≥ 1.5 or prothrombin activity < 40%)
complicated within 4 weeks by clinical ascites and/or
encephalopathy in a patient with previously diagnosed or
undiagnosed chronic liver disease/cirrhosis, and is associated with a high 28-day mortality.” (I, A).
Defining the acute insult
The spectrum of acute insult in the Asian region was revisited, while hepatitis B reactivation remains the predominant
cause of acute hepatic insult in the East, from the global
perspective. The trends showed an increase in the proportion
of alcoholic hepatitis over the years. This was a bit unexpected for the Asian countries where alcoholic hepatitis is
emerging as a major acute insult and shows the growing
westernization of Asia. A review of the recent CANONIC
study data showed that in the West the term precipitating
event is generally used and probably details of events such
as Hepatitis B or superadded hepatitis A and E are rarely
encountered or recorded [11]. Surprisingly, even the active
alcohol abuse and alcoholic hepatitis were also not the predominant causes. A plausible explanation could be that since
the CANONIC study only recorded the acute decompensation of cirrhosis and not the hepatic insults, the major events
recorded were only non-hepatic, such as bacterial infections
or sepsis. Acute decompensation of cirrhosis is a different
entity than ACLF. As the core premise of ACLF is presentation as liver failure, the acute insults should be hepatic
insults. Both hepatotropic and non-hepatotropic insults
should manifest in the patient first with liver failure.
Acute hepatic insults of infectious etiology included reactivation of hepatitis B virus (HBV) as the leading cause of
ACLF in the Asian region [12–20]. Reactivation of HBV
could be either spontaneous or due to intensive chemotherapy or immunosuppressive therapy [12, 13], immune restoration after highly active antiretroviral therapy for HIV [14,
15], treatment related [16], or reactivation of the occult HBV
infection by rituximab (anti-CD20)-based chemotherapy
[17–19]. Similarly, reactivation of hepatitis C virus infection
has also been reported, especially after immune suppressive
therapy [20, 21]. The other very important infectious etiology of the acute event is super-infection with hepatitis E
virus, predominantly in patients in the Indian subcontinent
[22–25]. Various bacterial, parasitic, and fungal infections
may affect the liver. Spirochetal, protozoal, helminthic,
or fungal organisms may directly infect the liver, whereas
bacterial or parasitic infection may spread to the liver from
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other sites [26]. These infections may lead to liver failure
in patients with underlying chronic liver disease. Among
the non-infectious etiologies, alcoholic hepatitis is the major
cause of acute deterioration in stable known or unknown
chronic liver diseases, more often in the western countries
[27, 28]. It was not clear what should be the interval from
the last alcoholic drink to be included as acute insult. Since,
after the direct hepatic injury, the immunological injury
starts to decline [29], a period of 28-day was considered
adequate for inclusion as the last drink. The issue, which
remained to be addressed, was of binge drinking in patients
with ACLF due to recent alcohol intake. It was appreciated
that a prospective data collection including the drinking
behavior especially in the past 6 months would help decide
the influence of drinking behavior on the clinical outcome
and help in defining the time frame of what should be considered as an acute insult (Fig. 2).
(A) Drug-induced liver injury (DILI) presenting as
ACLF is an important entity less often addressed in the
Global literature. Hepatotoxic drugs and complementary
and alternative medicines (CAM) are important causes for
acute and acute-on-chronic liver failure in the Asia–Pacific
region [30]. While most drugs are safely tolerated in the
setting of CLD, recent work suggests that individuals with
CLD may be at increased risk to develop hepatotoxicity at
least to certain drugs [31]. Hepatitis following the use of
anti-tubercular drugs was considered to be an important
cause of acute insult leading to ACLF. In a proportion
of patients, despite a history of use of CAM, the precise
nature and injurious influence of the agent cannot be
determined. Results from the drug-induced liver injury
network have demonstrated that mortality in 89 patients
with pre-existing liver disease was 16% which was significantly higher than the 5% mortality in 810 patients
with underlying liver disease [32]. Drugs such as antituberculosis drugs, methotrexate and antiretroviral drugs
in HIV/AIDS-infected individuals have been implicated
as triggering liver injury include particularly in the setting
of underlying chronic liver disease due to hepatitis B or
C [33–37]. Paradoxically CLD or cirrhosis is a risk factor
for tuberculosis [38, 39] and first-line anti-tuberculosis
drugs have been consistently shown to increase the risk of
hepatotoxicity, particularly in hepatitis B and C [40, 41].
Although drugs have been listed as a precipitant factor
in ACLF, data are scarce except from the APASL/AARC
database. Data from the West is lacking on drugs as an
acute insult leading to ACLF. In Asia 1.8% [42] to 5.7%
[43, 44] precipitating events for ACLF are related to drugs.
In Chinese cohort, the drugs were mostly from herbal or
traditional medications to anti tuberculosis drugs in Indian
cohorts [44]. From the AARC database, 329 (10%) of the
3132 patients of ACLF had an inciting event due to drugs.
There is, however, need for further data and work on the
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modes of hepatic injury caused by different herbal and
medicinal preparations on patients with cirrhosis.
(B) Autoimmune hepatitis flare leading to ACLF has not
been adequately addressed in both Asia Pacific as well as
Western cohorts. The pattern of clinical presentation spans
from benign chronic hepatitis and indolent disease to acute
liver failure. The abrupt presentation can indicate spontaneous exacerbation of a pre-existent chronic disease (presenting as ACLF), newly developed disease (presenting as ALF),
a superimposed infectious or toxic injury, or new disease
after viral infection, drug therapy, or liver transplantation.
Approximately, 20% of patients with autoimmune hepatitis
present with severe jaundice, HE and coagulopathy, with or
without ascites, which resemble ALF or ACLF [45]. The
disease usually has an unusual presentation with nearly half
the patients being seronegative, requiring a lower threshold
for transjugular liver biopsy. The histological features are
distinct from those found in fulminant AIH. Stravitz et al.
[46] identified lymphoid aggregates, perivenulitis and massive hepatitic necrosis as suggestive histological features
of AIH–ALF [47]. The multicentric AIH-ACLF data from
AARC database, which showed that the lymphoid aggregates
and perivenulitis are less common in AIH-ACLF. However,
advanced fibrosis (F3/F4), ductular reactions, and large areas
of parenchymal collapse with lymphoplasmacytic inflammation are prominent findings along with classical autoimmune
features in AIH-ACLF. It was observed that use of steroid

in a select group of moderately severe AIH has a favorable
outcome. Autoimmune hepatitis (AIH) was the first liver
disease for which an effective therapeutic intervention was
provided and treatment efficacy shown [47].
(C) Acute variceal bleeding has been included as one of
the events to define acute decompensation in the natural
history of cirrhosis [48]. Variceal bleeding has also been
taken as an acute insult for ACLF in some western trials of
ACLF. A scenario may exist that a patient who has already
fulfilled the criteria of ACLF and has been diagnosed
ACLF, develops a variceal bleed. In such a patient, variceal
bleed would be considered as a complication in the natural
history of ACLF. In recently analyzed 1028 compensated
cirrhosis patients presenting with acute variceal bleed, the
syndrome of ACLF was seen in 4% cases. Acute variceal
bleed led to 10% mortality in compensated cirrhosis, which
increased to 18% in 90-day follow-up with the development
of ACLF (p < 0.001). A large set of data was mined and the
issue was debated whether to consider variceal bleed as
an acute event of ACLF. However, since the definition of
ACLF includes liver failure, jaundice and coagulopathy, the
variceal bleed should result in liver failure. The liver failure
in such patients is likely to be due to hepatic ischemia [49]
and subsequent bacterial infections [50]. It was discussed
that for a patient with portal hypertension and cirrhosis
of the liver who presents for the first time with variceal
bleed without any previous or present signs or symptoms of

Fig. 2  Sequence of events in Diagnostic Criteria of ACLF: East vs.
West. The figure clearly describes the sequence of organ failure and
its mechanism. An acute hepatic insult leading to hepatic decompensation is the driver and subsequent extrahepatic organ failure is due
to failure of recovery/regeneration and development of sepsis after a
Golden Window. With consideration of sepsis as the intiating factor
and development of extrahepatic organ involvement as a part of defi-

nition leads to late identification of the ACLF patients where the therapeutic windos is lost. The difference between ACLF, AD and ESLD
(as in Fig. 1) is blurred and entity is heterogenous. So pure hepatic
insult leading to hepatic failure at the beginning and subsequent
extrahepatic organ failure as complication, not defining complex is
the crux in managing this group of liver disease patient
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chronic liver disease, it would not constitute an acute insult.
This is especially relevant if such a patient does not develop
any jaundice. The experts discussed the stratification of
patients based on the stage of underlying liver disease and
the severity of variceal bleed. Based on the data, it was
unanimously agreed that acute variceal bleeding is not an
acute hepatic insult unless in the patients where it produces
jaundice and coagulopathy fulfilling the criteria of ACLF.
(D) Acute HVOTO or PVT presenting as ACLF is a novel
concept. The disease burden, clinical picture, prognosis and
treatment strategies of BCS or PVT presenting as ACLF
are largely unknown. The thrombophilic disorders in those
with ACLF have not been evaluated but are unlikely to be
different from those without ACLF. The reduction of hepatic
blood flow due to acute PVT may lead to ischemic liver
injury [51]. The diagnosis of acute-on-chronic BCS in the
study by Langlet et al. was based on the presence of both
acute and chronic features, clinically and/or radiologically
[52]. However, the entity of ACLF was not described at that
time and it is unclear if any of these patients would have
fulfilled the criteria of ACLF. However, it was reported
that these patients had worse outcome as compared to other
patients with Budd–Chiari syndrome. Evaluation of thrombophilic disorders in patients with PVT or BCS and ACLF
should be similar to those without ACLF. There is no evidence currently to suggest that non-cirrhotic portal fibrosis
or EHPVO may present as ACLF.
The issue of other non-hepatotropic insults which have
been considered in other studies such as surgery, trauma,
insertion of transjugular intrahepatic portosystemic shunt,
trans-arterial chemoembolization or radiofrequency ablation
for hepatocellular carcinoma was discussed in detail. While
there is an indirect connection with each of these, it was
debated that a patient who already has cirrhosis with HCC
or a cirrhotic who undergoes surgery, separate risk scores are
already in practice and being utilized. The likely potential
for hepatic decompensation would vary depending on the
nature of intervention and underlying hepatic reserve. It was
agreed that non-hepatotropic insults producing direct hepatic
insult and ACLF in an otherwise compensated liver disease
could be considered as acute hepatic insults. In a proportion
of patients in Asia or even in the west, the precise agent(s)
leading to acute hepatic insult are not well recognized on
routine assessment. In such patients, this should be recorded
as such.
Recommendations
2.1.		 Defining the acute event in ACLF.
2.1.1. Infections.
2.1.1. Hepatotropic infections.
2.1.1.1.	Hepatotropic viral infections: In this group, reactivation of Hepatitis B virus (HBV) infection
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and super-infection with hepatitis virus are the
major causes of acute insults for precipitating
ACLF (1, A).
2.1.1.2	Hepatotropic non-viral infections: These include
bacterial, parasitic, and fungal infections precipitating liver failure and ACLF (2, C).
2.1.2.	Non-hepatotropic infections.
2.1.2.1.	Bacterial infection is unlikely to be the precipitant
in individuals with a definite hepatotropic acute
insult (2, B).
2.1.2.2.	Bacterial infections, if they primarily precipitate
hepatic failure, and present as ACLF, may be considered as a precipitant of ACLF, but data at present
are inadequate to demonstrate that infection per se
could lead to jaundice and liver failure (2, C). Druginduced liver injury (Drugs, CAM & HDS)—with
or without cirrhosis.
2.1.2.1.	Drug-induced ACLF (ACLF-D) is a distinct entity
than DILI [1, A].
2.1.2.2.	Diagnosis of ACLF-D is challenging as liver disease-related fluctuations in the liver function tests
may be part of the natural history of the disease
and may confound the diagnosis. Further, cirrhotic
patients may not show marked derangements in
transaminases [1, B].
2.1.2.3.	Those who develop ACLF-D are likely to have
severe consequences including decompensation
and death (1, B).
2.1.2.4.	D rugs responsible as acute insults, triggering ACLF-D in cirrhosis patients include antitubercular drugs, Complimentary and alternative
medications, antiretroviral drugs and Methotrexate (1, B). More evidence is needed for drugs like
azithromycin, azole antifungals and antimicrobials in cirrhotics (2, B).
2.1.2.5.	Risk of liver injury is proportional to the number
of hepatotoxic drugs in anti-TB regimen (2, C).
2.1.3.	Autoimmune liver disease—distinction in presentation as ACLF and ALF.
2.1.3.1.	ACLF-AIH frequently presents as seronegative for
autoantibodies or normal IgG levels [B2]. Seronegative AIH cases might be overlooked without
histology [1, B].
2.1.3.2.	Diagnosis of ACLF-AIH requires liver biopsy (transjugular route preferred). Biopsy is more helpful in
patients where etiology is not evident; antibodies
and IgG are negative but there is a high index of
suspicion (like extrahepatic features of autoimmunity/family history of autoimmunity or autoimmune
diseases like vitiligo, thyroiditis) [1, B].
2.1.3.3.	Frequency/degree of fibrosis may define chronicity
(ACLF or ALF), but fibrosis may progress in a few
weeks from F0 to F1–2 [2, C].
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2.1.3.4.	Corticosteroid therapy should be considered for a
select group of patients presenting with ACLF-AIH
[2, B].
2.1.4.	Acute variceal bleed.
2.1.4.1.	T he frequency of acute variceal bleed (AVB)
increases with severity of cirrhosis [2, B}.
2.1.4.2.	AVB in compensated cirrhosis (Child A) leads to
the development of ACLF in less than 5% cases
[2, B].
2.1.4.3.	Mortality in compensated cirrhosis increases with
the development of ACLF in 90 day follow-up postvariceal bleed [2, B].
2.1.4.4.	Incidence of post-EVL ulcers in ACLF is higher
than that in cirrhosis [1, C].
2.1.4.5.	Though infrequent, AVB can lead to ACLF in small
proportion of Child A patients. Further studies are
required in patients with Child B [2, C].
2.1.5.	Vascular liver diseases (PVT, HVOTO).
2.1.5.1.	In patients with cirrhosis, development of acute
occlusive portal vein thrombosis (PVT) may precipitate ACLF in a small sub-group (2, C).
2.1.5.2.	In patients with cirrhosis or Budd–Chiari syndrome, development of acute hepatic vein thrombosis (PVT) may precipitate ACLF (2, C).
2.1.5.3.	Patients with Budd–Chiari syndrome (BCS) may
infrequently present with or develop ACLF (2, C).
2.1.5.4.	Evaluation of thrombophilic disorders in patients
with PVT or BCS and ACLF should be similar to
those without ACLF (2, C).
2.1.5.5.	There is no evidence currently to suggest that noncirrhotic portal fibrosis or EHPVO may present as
ACLF (2, C).
2.1.5.6.	No data are available about the natural history or
outcome of patients with PVT or BCS presenting
with ACLF and no recommendations can be made
for management of patients with vascular liver diseases and ACLF (2, C).
Defining the underlying chronic liver disease
Two aspects were carefully analyzed, what constitutes
chronic liver disease, cirrhosis alone or non-cirrhotic chronic
liver diseases and the etiology of the chronic liver disease.
The degree of hepatic fibrosis and the functional hepatocellular mass remains heterogeneous in patients with the chronic
hepatitis [53, 54]. Even in patients with stage IV fibrosis, critical mass varies according to the parenchymal reserves. Modified Laennec Scoring System divides stage IV further, according to the thickness of septa into three, ending up in six stages
altogether [55, 56]. Moreover, ACLF is not equivalent to the
acute decompensation of cirrhosis, which has protean manifestations. Majority of the ACLF patients present with liver
failure without any previous assessment of liver disease. It is not
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possible to distinguish accurately the natural history of patients
with different degree of fibrosis presenting with ACLF at this
point in time. The liver with any significant degree of fibrosis,
with activated stellate cells, and infiltrated by the inflammatory
cells, is expected to respond in a different way to the acute insult
compared to the liver without inflammatory infiltrate [57].
NAFLD is the leading cause of donor rejection in liver
transplantation [58]. Experience from liver transplantation
centers shows that steatosis greater than 30% in the donor
liver is associated with a higher risk of primary non-function
and graft initial poor function as compared to grafts with no
or less than 30% steatosis [59]. Patients with metabolic syndrome and fatty liver, diabetics, male patients of age greater
than 45–50 years, and patients with obesity and dyslipidemia
have increased risk of fibrosis [60]. While cirrhosis could be a
late event, a large proportion of patients may have stage 2 or 3
fibrosis. Hence, NASH is indeed an important cause of chronic
liver disease [61]. Furthermore, in the East, a large proportion
of patients do have reactivation of chronic hepatitis B. In these
patients, while liver failure and ACLF-like presentation do
develop, cirrhosis is not necessarily present. The AARC data
based on the liver biopsy studies corroborated the facts that a
fair proportion of patients with ACLF do not have full-fledged
cirrhosis, but still carry a poor prognosis, with mortality above
33% at 4 weeks. Based on the current data set, and published
literature and the validity of the 2009 consensus on including
the non-cirrhotic chronic liver disease were reaffirmed.
Accurate and reliable assessment of underlying CLD in
the setting of ACLF is important for the subsequent management and need for liver transplant in these patients. Diagnosis of chronic liver disease in the setting of ACLF is made
by history, physical examination, and previously available
or recent laboratory, endoscopic or radiological investigations [62]. Ultrasound and CT abdomen may pick up CLD.
However, to assess the degree of fibrosis in an un-shrunken
liver would require other radiological modalities. The current non-invasive tests cannot clearly diagnose the presence
of chronic liver disease in the presence of inflammation and
liver failure. Hence, liver biopsy through the transjugular
route or occasionally through laparoscopy remains an important tool to confirm the stage of fibrosis and presence of
cirrhotic or non-cirrhotic liver disease.
A liver biopsy through the transjugular route may be of
help when the presence of already underlying CLD and the
cause of liver disease are not clear. The liver biopsy may
highlight the etiology, stage of fibrosis, prognosis and outcome in patients with ACLF [63]. In addition, transjugular access directly into the hepatic vein allows the hepatic
venous pressure gradient to be measured (HVPG). There is
a risk of bleeding leading to hemobilia, hemoperitoneum,
and hepatic hematoma in the setting of the deranged clotting profile [64]. The need of liver biopsy in ACLF should,
therefore, be individualized. Standardization of liver biopsy
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assessment would help a uniform approach to the diagnosis
and treatment of CLD and the acute insult.
There is a need to have reliable non-invasive tools to
assess the severity of fibrosis in a previously undiagnosed
CLD. Ultrasound and CT abdomen may pick up CLD. However, to assess the degree of fibrosis in an unshrunken liver
would require other radiological modalities. Transient elastography is a good modality to detect hepatic fibrosis [65].
However, the liver tissue stiffness may also increase with
hepatitis, steatosis, and inflammation present in the ACLF
setting [66].
The second issue was about the etiology of chronic liver
disease and cirrhosis in the Asian pacific region. The experts
reviewed the data from the AARC database and the etiologic
profile of cirrhosis in ACLF was found to be similar to etiology of cirrhosis in general in the respective countries [28,
67, 68]. With the rising incidence of obesity and NAFLD,
a proportion of burnt-out NASH presenting as cryptogenic
cirrhosis also increases [69–71]. Viral serology and nucleic
acid testing are required to identify viral etiology. Specialized tests to diagnose metabolic and autoimmune diseases
are needed as well. The presence of stigmata of liver disease
on clinical examination, low platelets, evidence of synthetic
dysfunction in previous reports, and altered AST/ALT ratio
in previous reports should prompt the diagnosis of the presence of CLD [72, 73].
Recommendations
2.2.		 Defining the underlying CLD:
2.2.1.	Cirrhotic and non-cirrhotic chronic liver diseases
qualify as chronic liver diseases (1, A).
2.2.2.	The common underlying chronic liver diseases
include alcohol, hepatitis B, hepatitis C, NAFLDrelated chronic liver disease or cirrhosis of the liver
(1, A).
2.2.3.	Chronic hepatitis and/or significant fibrosis without
cirrhosis should be taken as a chronic liver disease,
if such a patient presents as ACLF (1, B).
2.2.4.	NAFLD-related chronic hepatic injury; NASH, if
associated with significant fibrosis, should be taken
as a chronic liver disease in ACLF (1, B).
2.2.5.	Patients with known previous decompensation with
jaundice, HE, and ascites should be excluded (1, C).
2.2.6.	Diagnosis of chronic liver disease and cirrhosis in
the setting of ACLF is made by history, physical
examination, laboratory, endoscopic or radiological
investigations (1, A).
2.2.7.	A liver biopsy through the transjugular route may
be helpful when the presence of underlying chronic
liver disease and/or the cause of chronic liver disease and/or the acute insult is not clear (1, B).
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Impact of comorbidities and obesity
Comorbidities also influence the outcome of ACLF as far as
the disease and outcome are concerned. The presence of comorbidities like obesity, sarcopenia and other metabolic risk
factors like diabetes mellitus, hypertension and dyslipidemia
have a bearing on the outcome of patients with cirrhosis
[74]. However, there is a sparse literature on the effect of
obesity, sarcopenia and other metabolic risk factors on the
severity and outcome of patients with acute-on-chronic liver
failure (ACLF). In a recent analysis of the AARC database,
the prevalence of metabolic risk factors and its impact on the
severity and outcome were analyzed in patients with alcoholrelated ACLF as per the APASL definition [75]. In a recent
report, of the 1028 patients from AARC database, 15%
patients had history of overweight or obesity, 14% of T2DM,
7% of HT and 15% of dyslipidemia. Patients with metabolic
traits compared with control group, had more severe disease;
those with overweight or obesity had significantly higher
MELD score and those with dyslipidemia had higher AARC
score. None of the other metabolic risk factors either alone
or in combination had any impact on the severity of ACLF.
The presence of overweight or obesity was also significantly
associated with increased day 30 mortality while none of the
other metabolic risk factors, alone or in combination were
associated with day 30 or 90 mortality [75]. In addition to
above, alcohol intake and subsequent chronic liver disease
with or without cirrhosis is another co-morbid condition.
Recommendations
2.3.		 Impact of comorbidities and obesity.
2.3.1.	The presence of overweight or obesity and dyslipidemia increases the severity of liver disease in
ACLF patients (1, B).
2.3.2.	The presence of overweight or obesity increases
the short-term (30 day) mortality in patients with
ACLF (1, B).
2.3.3.	There is need to compare the development and
natural history of ACLF in patients with NASH
versus NASH cirrhosis (2, C).
Changing trends for the etiology of acute insult and chronic
injury
The epidemiology of acute insult has changed significantly in the past 5 years. In the recent AARC data, alcohol
has now emerged as the most common etiology for acute
insult (49%) as well as for underlying chronic liver disease
in contrast to previuos data of HBV predominance. DILI
and autoimmune etiologies have shown increasing trend;
however, HAV/HEV had decreasing trend. HBV infectioninduced ACLF as well as HAV/HEV-induced ACLF is now
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showing a decreasing trend over time, whereas alcohol and
herbs, drugs and supplements (HDS)-induced ACLF show
an increasing trend. The unknown causes for acute insult and
chronic injury constitute only 5–15% cases of ACLF in the
East in contrast to the West, where these are seen in about
40% of ACLF patients.
Recommendations
2.4.		Changing trends for the etiology of acute insult
and chronic injury.
2.4.1.	Alcohol is now the commonest etiology for acute
hepatic insult as well as for the underlying chronic
liver disease in the Asian continent [2, B].
	2.4.2.	DILI and autoimmune etiologies have shown
increasing trend [2, B].
	2.4.3.	HBV infection–reactivation of hepatitis B-induced
ACLF as well as acute HAV/HEV-induced ACLF
shows a decreasing trend over time in certain
regions, whereas alcohol and herbs, drugs and supplements (HDS)-induced ACLF show an increasing
trend (1, A).
	2.4.4.	The unknown causes for acute insult and chronic
injury constitute only 5–15% cases of ACLF in the
East in contrast to the West, where these are seen
in about 40% of ACLF patients (1, A).
ACLF is distinct from acute decompensation (AD):
differentiating AD and ACLF
The two disease entities look similar and are often misunderstood. The experts reviewed the literature and presented their
data. The data from the AARC database were presented. The
discussion revolved around the following main issues:
Acute decompensation occurs in a cirrhotic with or
without prior decompensation and is often associated with
a precipitant [6]. The presentation of AD is either hepatic
(jaundice, ascites, HE) or extrahepatic (variceal bleed, acute
kidney injury or sepsis), and time period is up to 3 months
[11]. The level of jaundice could be well below 5 mg/dl,
below the cutoff generally taken for liver failure. The precipitant for AD can be hepatic (48%) or non-hepatic (46%).
Ascites/HE/AVB may precede jaundice. There could be
several combinations in the acute decompensation; such as
jaundice with or without ascites, HE alone or with ascites
with or without jaundice, HE variceal bleed alone or with
ascites, sepsis with jaundice or alone, etc. Each of these entities is in themselves, a well-defined complication, and has
been extensively studied in patients with cirrhosis. Moreover, AD can be the index event or it could be a repeat event
in patients with prior decompensation. Hence, there are multitudes of combinations possible in a patient presenting with
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AD. After due deliberations, it was unanimously felt that AD
should be considered as a recordable time point, an unfavorable event, in the natural history of cirrhosis rather than
a syndrome by itself. The precise type of acute presentation
of the patient should be recorded and the patient should be
accordingly monitored and managed.
The overall mortality in patients with AD at 1 and
3 months was 23% and 29%, respectively, much lower than
when patients develop ACLF. The probability of reversal,
progression to end-stage liver disease and need for a liver
transplantation would depend on the presentation of the AD
such as variceal bleed or ascites. Role of bridging therapy
and emerging therapies in AD is largely unknown.
Acute-on-chronic liver failure (ACLF) is a syndrome of
hepatic decompensation (jaundice, coagulopathy, ascites
and/or HE), where the insult is only hepatic and leads to liver
failure in a period of 4 weeks [2]. Jaundice and coagulopathy
precede development of ascites. Non-hepatic organ failure,
i.e., AKI, sepsis, AVB develops after the ACLF syndrome or
less commonly, with the onset, depending on the severity of
liver failure. The presentation is index, occurring in a patient
of chronic liver disease with or without underlying cirrhosis
of the liver. The hepatic reserve may show recovery leading
to complete reversal of the syndrome as well as regression of
fibrosis and portal hypertension. The long-term survival, i.e.,
after 24 months of index presentation with ACLF is better
than the AD cohort [HR: 1.94 (1.17–2.21), p < 0.01] [76].
The progression of disease and onset of multi-organ failure
are faster in the non-salvageable cohort with a high 3-month
mortality of 54% [77].
Development of ascites represents a state of acute portal hypertension in ACLF patients. This rapid rise in portal
pressure is a result of severe hepatic inflammation and ongoing liver failure. Highly activated stellate cell population,
cytokine storm and ongoing hepatic parenchymal necrosis
perpetuate the portal hypertension syndrome. The use of
non-selective beta-blockers has been shown to be effective
in reducing the mortality and risk of variceal bleed in ACLF
patients.
ACLF is a unique disease entity and is distinct from
acute decompensation by considering only those patients
who have one type of AD and in a specified time frame of
28 days; this includes patients who develop after a hepatic
insult, jaundice and coagulopathy followed by development of acute portal hypertension in the form of ascites
and or HE (Table 3).
Recommendations
	2.5.	ACLF is distinct from acute decompensation (AD):
differentiating AD and ACLF.
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	2.5.1.	Natural history and outcome of ACLF.
	2.5.1.1.	The main etiologies for ACLF are alcohol-related
injury, viral hepatitis, drug-induced liver injury,
and autoimmune liver disease. In the Asian Pacific
region, in only about 5–10% of the cases, the acute
insult is unidentifiable [1, A].
	2.5.1.2.	Age and the presence of cirrhosis are independent
risk factors for mortality in ACLF (1, B).
	2.5.1.3.	Portal hypertension with an HVPG greater than
18 mmHg and/or variceal bleeding, presence of
complications including ascites, SBP and encephalopathy are independent predictors for mortality (2,
B).
	2.5.1.4.	Starting NSBBs is safe in ACLF and its use is associated with improved short-term survival (2, B).
	2.5.1.5.	Appropriate management has key impact on the
outcomes of ACLF, early (within 2 weeks) antiHBV treatment for HBV-ACLF, corticosteroid
therapy for alcoholic ACLF and AIH-ACLF are
worthwhile options (1, B).
	2.5.2.	Natural history and outcome of acute decompensation.
	2.5.2.1.	Acute decompensation (AD) is currently defined
as acute occurrence of decompensating events
(ascites, HE, jaundice, variceal bleed or bacterial
infection) in a patient with CLD (1, B).
2.5.2.2.	Patients with AD who have or progress to develop
extrahepatic organ failure have high short-term
mortality (1, A).
2.5.2.3.	Early evaluation of potential predictors and precipitating agents can help in managing these patients
(1, B).
	2.5.3.	Acute decompensation—differentiating from
ACLF for clarity in definition.

	2.5.3.1.	AD develops in a patient with chronic liver disease/
cirrhosis, with or without prior decompensation,
and is often associated with an identifiable precipitant and develops in less than 3 months [2, A].
	2.5.3.2.	Any decompensation preceding jaundice strongly
favors AD [1, B].
	2.5.3.3.	Absence of repeated episodes of decompensation
differentiates ACLF as a unique syndrome [2, A].
This has implication on the management decisions
and prognostication, including reversibility of the
syndrome.
	2.5.3.4.	Long-term survival, reversal and/or recovery of
hepatic reserve has been documented with ACLF
[2, A].
	2.5.4.5.	The differentiating features between different presentations of AD and the ACLF need to be studied
carefully by expanding the AARC database [3, C].
Role of Liver histology in ACLF
Since the previous consensus statement, new data and
insights into the liver histopathology have become available.
The main questions that were addressed in the current consensus meeting were: (1) Is liver biopsy feasible and safe in
ACLF, (2) Can liver biopsy help to differentiate ACLF from
ALF and chronic liver disease, (3) Are there any histological predictors of outcome in ACLF, such as need for liver
transplantation or mortality and (4) Are there any differences
in regenerative response in sequential biopsies of survivors
and non-survivors?
Percutaneous liver biopsy is generally not feasible in
patients with ACLF due to coagulopathy and ascites. Transjugular liver biopsy (TJLB), on the other hand, is considered relatively safe and can help assess stage of fibrosis and
severity of hepatic injury. For example, severity of alcoholic
hepatitis in alcoholic liver disease-related ACLF could be
assessed only by liver biopsy [63]. It can provide clues to the
underlying acute insult as in Wilson’s disease, malignancy,
autoimmune hepatitis, DILI and NASH [78, 79].

Table 3  Differentiating ACLF from acute decompensation
Parameter(s)

Acute-on-chronic liver failure (ACLF)

Acute decompensation (AD)

Presentation

Hepatic insult
Index
In up-to 95% cases
Within 4 weeks
May or may not be present
No
33–51%
In half of cases

Hepatic or non-hepatic
Can be index or subsequent
In up to 70% cases
Up to 12 weeks
Always present
With or without Prior Decompensation
23–29%
Uncommon

Identifiable precipitant
Time from insult to presentation
Underlying cirrhosis
Prior decompensation
Mortality at 1 and 3 months
Reversal or recovery
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Mini-laparoscopic liver biopsy is another alternative
for getting liver biopsy in patients of advanced cirrhosis with acceptable bleeding risk. More data needed on
this modality and comparison with TJLB are lacking at
present. However it can be considered in areas with poor
access to TJLB and biopsy is definitely needed for the
decision- making [80].
Differentiating ALF and chronic hepatitis with flare
is based on findings of fibrous bands (spurs and bridges)
and ductular proliferation. Features of cholestasis and
bile duct proliferation are more common in patients with
acute injury (classical features of acute hepatitis along
with cellular and ductular cholestasis are indicative of
acute injury). Differentiation between cirrhosis with acute
deterioration and compensated cirrhosis is based on the
presence of necrosis and features of acute hepatitis in the
former group of patients [63]. It was proposed that the
diagnostic stains for fibrosis and necrosis be mentioned. It
was also proposed that connective tissue stains (especially
Shikata’s orcein) should be done in all such cases for differentiating necrosis from fibrosis.
Liver histopathology could be very useful in prognosticating the outcome in a patient with ACLF [63, 81]. The
extent of necrosis, liver damage and fibrosis is helpful. The
presence of ductular bilirubinostasis on liver biopsy defined
as the presence of bile plugs in dilated ductules at the interface between the portal tract and parenchyma predicted a
poor outcome and a high potential for development of infections in ACLF. While ballooning was helpful, suggestive of
regenerating potential, the presence of eosinophilic degeneration of hepatocytes was not a favorable feature. Standardization of liver biopsy assessment is essential for a uniform
approach to the diagnosis and treatment of CLD and acute
insult.
Liver regeneration is considered to play an important
role in ACLF as prognosis can be improved if the critical
threshold of functional liver cell mass is regained. Decompensated cirrhosis is considered irreversible owing to loss
of regeneration potential. Liver histology can provide morphological evidence supporting these concepts and for
assessing regenerative potential and prognosis [82]. In this
report, immuno-histochemical study of two levels of regenerative responses in liver failure revealed that proliferating
hepatocytes were significantly more in ALF in comparison
to ACLF (p < 0.001) and CLD (p < 0.001).
There is significant relationship between HSCs and presence of HPCs, indicating a possible dynamic role of HSCs
in liver regeneration and pathobiology of ACLF [83]. Liver
biopsy is an important mode of understanding and validating the results of clinical trials exploring various therapeutic
options for, e.g., mobilization of bone marrow-derived stem
cells with granulocyte colony-stimulating factor (GCSF)
[84].
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Recommendations
	2.6.		Role of liver histology in ACLF.
	2.6.1.	A liver biopsy through the transjugular route is
helpful to diagnose/confirm the cause of acute
injury [1, B].
	2.6.2.	Liver biopsy is helpful in patients where the presence and stage of underlying chronic liver disease
and/or the cause of chronic liver disease are not
clear (2, A). Biopsy can help identify unsuspected/
multiple etiologies, i.e., primary and concomitant
etiologies.
	2.6.3.	The need of liver biopsy in ACLF should be individualized, especially in alcoholic hepatitis, severe
autoimmune hepatitis, and flare of Wilson disease
(2, A).
	2.6.4.	Liver biopsy indicates the stage of fibrosis and is
helpful in the prognosis and outcome in patients
with ACLF (B 1). It can help in distinguishing
ACLF from decompensated cirrhosis [1, B].
	2.6.5.	Certain histologic parameters are predictors of
prognosis of ACLF, like ductular bilirubinostasis,
eosinophilic degeneration, and parenchymal extinction (1, B).
	2.6.6.	It can help in distinguishing ACLF from decompensated cirrhosis [1, B].
	2.6.7.	Standardization of liver biopsy assessment is essential for a uniform approach to the diagnosis and
treatment for CLD and acute insult (2, C).
	2.6.8.	Noninvasive tools to measure liver stiffness and
biomarkers may help in identifying patients with
advanced fibrosis. Studies are needed to validate
the performance of these tests in the setting of
ACLF (2, C).

Defining the liver failure in ACLF
Acute liver failure is generally defined as development of HE
within 4 weeks of onset of jaundice [1, 2]. Since the basic
premise in ACLF is to identify patients with chronic liver
disease or cirrhosis presenting as acute liver failure, the time
frame for liver failure was kept as 4 weeks [5].
The clinical presentations in ACLF is varied and depends
upon the severity of acute insult and degree of underlying
chronic liver disease. In the published reports, patients
included as having ACLF had severe jaundice associated
with organ failure manifested as either HE or hepatorenal
syndrome (HRS) [1, 2].
Defining the liver failure in ACLF, therefore, required a
detailed consideration of all the existing liver failure scores
and the criteria defining liver failure in the organ failure
scores such as SOFA and APACHE II. The two main variables are bilirubin and coagulopathy.
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Serum bilirubin analysis of the AARC data revealed
that patients with a bilirubin between 5 and 10 mg/dl also
had substantial mortality ranging around 38%. The data
for patients below this level were, however, not collected
as per the initial definition, but is likely to yield mortality rates much below 33%. On the other hand, in the
CANONIC study, the level of bilirubin for hepatic failure
was taken as 12 mg/dl so as to determine 15% mortality at
28 days. If these criteria were applied to the ACLF patients
in the Asian region, a much higher mortality was observed
in this cohort. After detailed discussion, the original value
of > 5 mg/dl was accepted as the cutoff for bilirubin for
defining liver failure [1, 2]. This was reiterated to be inclusive of less severe group of patients and enabling a complete spectrum of patients, including those who have a
potential for recovery [2].
Coagulopathy the presence and degree of coagulopathy
as a marker for liver failure were re-evaluated. Coagulopathy
is an important hallmark of severe hepatic dysfunction [59,
60]. Patients with ACLF have complex hemostatic defects
leading to a delicate, unstable balance between bleeding and
thrombosis [85].
Development of clinical ascites and/or encephalopathy
has been conventionally taken as evidence of hepatic failure
[1, 27]. Ascites and HE were not seen in all the patients and,
therefore, presence of either of them was accepted for the
definition of ACLF. In the AARC data, ascites was present
in 91% and HE in about 45% of the patients at presentation.
The data were further analyzed to see if a shorter interval
of 2 weeks instead of 4 weeks is a better cutoff for predicting mortality in patients with underlying cirrhosis who
developed jaundice followed by ascites. The analysis of the
AARC data showed that in patients who developed ascites
within 2 weeks against those after 2 weeks of onset of jaundice, though had a slightly more severe course, the differences in mortality were not significant.
Grade of liver failure for ACLF like in many conditions
in medicine, such as the NYHA classification for heart failure [86] severity of a disease or variable can be defined to
predict the outcome of the disease. Using the four variables,
bilirubin, INR, ascites and HE, a simple scoring system may
be helpful for making treatment strategies.
The basic premise for defining a syndrome is to identify a group of patients, who have a distinct presentation,
course and outcome. A prospective study using AARC database with 1402 patients from several centers across Asia
included a large derivation cohort of 480 patients to develop
a dynamic prognostic model, which was validated in subsequently enrolled 922 patients to predict outcomes including
mortality [3]. The results bring forth a simple ‘liver failure grading system’ for patients with chronic liver disease
based on variables, namely serum bilirubin, INR, grade of
HE, serum lactate and serum creatinine [43, 87–89]. Serum
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lactate levels are elevated in relation to degree of hepatocellular injury, inflammation and degree of tissue perfusion.
The analysis resulted in a simple ‘liver failure grading
system’ based on 5 variables; namely, serum bilirubin, INR,
serum lactate, serum creatinine and grade of HE. There is
no score dedicated to liver failure in cirrhotic patients, commonly recognized as a distinct entity, ACLF. The grading
system, i.e., Grade I for a score of 5–7, Grade II for 8–10
and Grade III for 11–15 with 28-day mortality of 12.7, 44.5
and 85.9%, respectively, was developed. The grades of liver
failure showed a potentially recoverable group (Gr. I), a
group that needs special monitoring (Gr. II) and a group
that demands immediate interventions for improved outcome
(Gr. III). The AARC model was found to be better than existing models for ACLF with an excellent predictability, i.e.,
in AUROC of 0.80 (derivation cohort) and 0.78 (validation
cohort). It is even more robust than recently reported models
[3] where the AUROC is below 0.80. The AARC-ACLF
score is dynamic in nature. It could predict day 7 (score of
9 or below) and day 28 survival at presentation (score of 9
or below). For a baseline score of ≥ 10, with each one unit
increase, the day 7 mortality increased sharply compared
to the patients who presented with a score of < 10 (20% vs.
4%). The score also predicted well the day 28 and day 90
survival. Thus, the AARC score provides a physician a window to decide early and explore definitive therapies including liver transplantation. Shift from grade I to III liver failure
at day 4 and day 7 increases the mortality significantly. At
the same time, the persistence of grade I or II liver failure
till day 7 predicted improved survival, while persistence in
grade III failure was uniformly severe and warranted early
consideration for transplant [3].
Recommendations
	3.0.	Defining the liver failure in ACLF:
	3.1.	Jaundice (serum bilirubin > 5 mg/dL [> 85 lmol/L])
and coagulopathy (INR > 1.5 or prothrombin activity < 40%) are mandatory parameters to assess liver
failure (1, A).
	3.2.	Ascites and/or encephalopathy as determined by physical examination also reliably reflect significant hepatic
functional impairment (1, A).
3.3.	Liver failure score (AARC score) which includes total
bilirubin, INR, grade of HE, plasma lactate and serum
creatinine reliably predicts the disease severity and
outcome (1, A).
	3.4.	Grading of liver failure as per AARC score I (5–7),
II (8–10), III (11–15) effectively prognosticates and
guides the therapy [1, B].
	3.5.	The assessment of coagulation system by global coagulation methods (viscoelastic technique/thrombin genera-
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tion test) may be considered as a useful tool for assessing
coagulation anomalies in ACLF patients (2, B).

Sepsis in ACLF
Sepsis is a syndrome of systemic inflammatory response of
the host to an identifiable infection. The systemic inflammatory response syndrome (SIRS) is defined by the presence of
at least two of the following criteria: (1) altered temperature,
(2) elevated respiratory rate or hyperventilation, (3) tachycardia, and (4) altered white blood cell count (high, low, or
immature forms) [67]. Sepsis is the most common cause of
mortality in most intensive care units (ICUs) [90–92].
Due to the hyperdynamic circulation and complications
of portal hypertension, the currently accepted clinical definition of SIRS and sepsis may not be entirely applicable
to patients with cirrhosis or ACLF. Hence, a high index of
suspicion is required for making a clinical diagnosis of sepsis in these patients. Liver failure initiates and predicts the
development of SIRS. New onset SIRS in the first week is an
important determinant of early sepsis, organ failure, and survival (Fig. 3). Prompt interventions in this ‘golden window’
before development of sepsis may improve the outcome of
ACLF [78].
Consideration of sepsis as an acute insult in the absence
of liver failure is confusing and with limited scientific basis.
Sepsis is a consequence rather than the cause for development of ACLF. The APASL definition does not include sepsis as a primary cause for liver failure, but in the Western
definition, sepsis is considered as the most common precipitant. The inclusion of sepsis in the definition is likely to
be associated with concomitant multi-organ involvement,
poor prognosis and would be unlikely to provide a targeted
therapy or a definitive therapy such as liver transplant.
SIRS is the inflammatory response to the damaged
organ in the host. It could be a result of sterile inflammation or an occult infection [93–95]. In fact, in 60% of
patients fulfilling the SIRS criteria, infection could not be
detected [78]. This highlights the limitations of the current techniques available to detect infections or may be
because of use of prophylactic antibiotics the detection of
organisms becomes difficult. Prevention of development
of SIRS or its progression from SIRS to sepsis by immune
modulation in the ‘Golden Window’ period could decrease
the incidence of organ failure and improve survival [78].
‘Golden window’ is a short period of about 1 week before
the onset of sepsis and development of extrahepatic organ
failure in a patient with ACLF. Therapeutic interventions
during this period are likely to prevent organ failure and
provide a potential opportunity for ameliorating or reversing the hepatic injury and failure [78].
The current paradigm regarding the host immune
response to sepsis is debated and is a matter of great
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interest in clinical trials as well as basic science. Two theories have been proposed to describe the host response to
sepsis. According to the most accepted theory, both proinflammatory and anti-inflammatory responses occur early
and simultaneously in sepsis although the net initial effect
of these competing processes is typically manifested by an
early, dominant, hyperinflammatory phase characterized by
shock, fever and hypermetabolism [96, 97]. Subsequently,
this initial hyperinflammatory phase evolves over several
days into a more protracted immunosuppressive phase [98].
The robustness of the hyperinflammatory phase depends on
numerous factors, including pre-existing co-morbidities,
nutritional status, microorganism load and virulence factors [99, 100].
According to the second theory, there is rapid and sustained upregulation of genes that regulate the innate immune
response and the simultaneous downregulation of genes that
regulate the adaptive immune response. There is protracted,
unabated inflammation driven by the innate immune system
with resultant organ dysfunction and failure [101].
Whether sepsis is the cause or a result of liver failure
was debated at length. The fact that patients who presented
with no SIRS or subsequently developed SIRS or sepsis over
a period of 1–2 weeks indicates that infection and sepsis
develop after liver failure and unabated inflammation leads
to immune paresis and provides an opportunity for infections and sepsis to occur. Non-hepatic infections are also
common in patients with ACLF [101, 102]. Neutrophil dysfunction and immune paralysis due to reduced HLA-DR
expression have been shown to rapidly develop in ACLF
patients [102–104]. The frequency of intrahepatic myeloid
and plasmacytoid dendritic cells is reduced with increased
interferon gamma producing CD8 T cells in patients with

SIRS

Sepsis

Organ
Failure

7 Days

Fig. 3  Golden window in ACLF. ACLF is the state of acute inflammatory response with cytokine burst. The SIRS is a response to this
inflammation and subsequent resolution of inflammation and recovery or persistence of inflammation (leading to Compensatory Antiinflammatory Inflammatory Response Syndrome-CARS) and sepsis.
Patients of ACLF in a period of 7 days develop SIRS (which can be
infective or sterile) but both the things lead to complications and sepsis develops subsequently. This time period is the therapeutic Golden
Window. SIRS needs consideration for organ support, antibiotics for
occult sepsis and prioritization for definitive therapy, i.e., liver transplant
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ACLF. Decreased frequency of DCs and high IFN-γ levels
correlate with poor patient survival [104].
Bacterial infection is present in about 1/3rd of ALCF
patients at presentation to a tertiary referral hospital, and
this further increases by first week [78]. The AARC data
showed that the patients presenting with sepsis, at baseline
or who developed new sepsis at day 4, have high mortality. Bacterial infection (BI) predicts development of organ
failure in ACLF. Organ dysfunction and organ failure are
significantly higher in infected cohort with high short-term
mortality. The acute phase proteins, such as C-reactive protein and procalcitonin, were proven to be reliable biomarkers
for bacterial infection. The most frequent infections are SBP,
pneumonia, UTI, and bacteremia. Second infection (2nd hit)
is associated with poor outcome in patients with ACLF. Hospitalized patients with ACLF should be monitored closely
for the presence of infections to enable early diagnosis and
treatment. Routine examination of blood and body fluids is
recommended. Patients who respond to treatment for bacterial infection have significantly reduced mortality. Patients
who respond to treatment for bacterial infection have significantly reduced mortality. As soon as bacterial infection
is diagnosed or suspected, broad spectrum antimicrobial
agents or combined use of antibiotics are preferred, thereafter the therapy is adjusted according to the results of
the sensitivity test. Empirical antibiotic therapy should be
based on environment, local resistance profiles, severity and
type of infection. To optimize the empirical antibiotic treatment, it is quite important to distinguish among community
acquired, health care associated and nosocomial infections.
Invasive fungal infection is not uncommon in ACLF
patients. However, data are minimal. The diagnosis of invasive fungal infection can be proven, probable or possible,
depends on mycological evidence, and clinical evidence.
Invasive pulmonary aspergillosis (IPA) is increasingly recognized as a cause of morbidity and mortality in patients
with ACLF. Prophylaxis of invasive fungal infection may be
applicable with echinocandins in selected patients. Prophylaxis with fluconazole followed by echinocandins needs to
be evaluated in ACLF patients. Predictors of poor progression (risk factors) include diabetes, AKI, ICU admission,
and admission for bacterial infection, prolonged antibiotic
therapy (> 5 days from admission), prior h/o hospitalization. Biomarkers such as galactomanan or B–D Glucan can
be used for supporting diagnosis if there is invasive fungal
infection in ACLF. Administration of albumin is recommended in patients with SBP for preventing from type-1
HRS and reducing mortality. The role of albumin in preventing or treating other infections in ALCF is not clear.
Recommendations
	4.0.	Sepsis in ACLF.

369

	4.1.	There is a central role of inflammation and dysbalance
of innate and adaptive immune responses in ACLF
patient (1, B).
	4.2.	It is difficult to differentiate SIRS from early sepsis in
cirrhosis (2, A).
	4.3.	Bacterial infection is present in about 1/3rd of ALCF
patients at presentation to a referral hospital, and this
may increase in the first week [2, B].
	4.4	Patients who do not have sepsis have low 28-day mortality [B2]. Patients with accompanying sepsis at baseline or who develop sepsis at day 4 have high mortality
[2, B].
	4.5	Organ dysfunction and organ failure are significantly
higher in infected cohort and this is attended with high
short-term mortality [2, B].
	4.6	Bacterial infection (BI) is an important factor to predict development of organ failure in ACLF. The most
frequent infections are SBP, pneumonia, UTI, and Bacteremia (1, A).
	4.7	Second infection (2nd hit) is associated with poor outcome in patients with ACLF [1, B].
	4.8	Hospitalized patients with ACLF should be monitored closely for the presence of infections to enable
early diagnosis and treatment. Routine examination of blood and body fluids is recommended (1, A).
	4.9	The acute phase proteins, such as C-reactive protein
and procalcitonin, have been proven to be reliable
biomarkers associated with infection and are recommended for screening for the presence of bacterial
infections (1, B).
	4.10	As soon as bacterial infection is suspected or diagnosed, broad spectrum antimicrobial agents alone
or in combination should be started and thereafter, the therapy should be adjusted according to the
results of the antibiotic sensitivity test results (1, A).
	4.11.	Empirical antibiotic therapy should be based on environment, local bacterial resistance profiles, severity
and type of infection. To optimize the empirical antibiotic treatment, it is quite important to distinguish
among community acquired, health care associated
and nosocomial infections (2, A).
	4.12.	Invasive fungal infection is not uncommon in ACLF
patients. These can be proven, probable or possible,
depending on mycological and clinical evidences (2,
B). Biomarkers such as galactomanan or B-D glucan
can be used for supporting the diagnosis (1, B).
	4.13.	Invasive pulmonary aspergillosis (IPA) is increasingly
recognized as a cause of morbidity and mortality in
patients with ACLF. Voriconazole plasma concentration monitoring may ensure the safety and efficacy of
ACLF patients with Invasive aspergillosis infection (2,
C).
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	4.14.	Prophylaxis of invasive fungal infection can be done
using echinocandins in selected patients (B2). Prophylaxis with fluconazole followed by echinocandins
needs to be evaluated in ACLF patients [1, C].
	4.15.	Predictors of poor progression (risk factors) of fungal
infections in ACLF are the presence of diabetes, AKI,
ICU admission, and admission with bacterial infection,
prolonged antibiotic (> 5 days pre-admission) and prior
hospitalization (2, B).
	4.16.	The value of qSOFA and Sepsis-3 criteria is unclear to
assess severity of infection in patients with ACLF.
	4.17.	Administration of albumin is recommended in patients
with SBP to prevent development of type-1 HRS and
reduce mortality (A2). The role of albumin in preventing or treating other infections in ALCF is not clear [2,
B].
	4.18.	Patients who respond to treatment for bacterial infection have significantly reduced mortality [2, B].

Organ dysfunction and organ failure in ACLF
The concept to differentiate organ dysfunction from organ
failure is useful in assessing the degree of organ damage and
predicting the probability of disease progression or regression; prioritizing the patient for liver transplantation and the
likelihood of futility of care or high probability of death.
The data from AARC database were carefully analyzed
with respect to defining organ dysfunction and organ failure
for each of the extrahepatic organs.
Renal failure
Renal failure in patients of ACLF is considered to be a complex and challenging condition that is associated with an
ominous prognosis. Further, kidneys are one of the most
frequent extrahepatic organs involved in patients with ACLF.
The EASL-CLIF consortium has defined ACLF in which
kidney dysfunction is used as a defining condition [11].
Hence, renal dysfunction or failure is universally present in
patients with ACLF with or without liver failure, according
to the definition by the EASL-CLIF consortium. On the contrary; the APASL definition of ACLF does not incorporate
kidney dysfunction in its definition [1, 2]. Studies based on
APASL criteria have reported renal dysfunction in 22.8–34%
of patients with ACLF and as high as 51% using the more
sensitive AKIN criteria [103]. This highlights the fact that
a significant number of patients of ACLF based on APASL
criteria who do not have renal dysfunction (using even the
most sensitive criteria to detect renal involvement) would
definitely be missed if renal dysfunction was considered in
the definition as per CLIF.
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In patients with decompensated cirrhosis, the main abnormality causing renal dysfunction is systemic and splanchnic
vasodilatation secondary to portal (or sinusoidal) hypertension which leads to decreased effective arterial blood volume
and activation of neurohormonal systems, the rennin–angiotensin aldosterone (RAAS), the sympathetic nervous system
and non-osmotic release of antidiuretic hormone, resulting in
sodium and water retention [104–106]. The systemic hemodynamic alterations in ACLF are similar to those in patients
with decompensated cirrhotics [107], but the pathogenesis
of renal dysfunction in ACLF is quite different; a major
role is played by SIRS and subsequent sepsis in patients of
ACLF but not in those with decompensated cirrhosis [108].
A higher prevalence of structural AKI has been reported for
patients with ACLF. In a large cohort study from the AARC
database, the concept of PIRO (defined as predisposition,
infection/inflammation, response, organ failure) was used
for creating a predictive model for understanding the pathophysiology of kidney dysfunction in patients with ACLF
[109]. Together, the components of PIRO reflect the role of
key factors, which result in development, and progression
of AKI in patients with ACLF. The PIRO, which is a composite score, derived from the AARC database accurately
predicted in patients with ACLF, highlighting the prognostic significance of kidney dysfunction in these patients. The
PIRO score can predict the development of AKI within first
15 days of diagnosis of ACLF and may help in stratification
for additional therapeutic interventions [109].
Serum creatinine is used for defining and staging AKI in
patients with cirrhosis. However, serum creatinine is influenced by various factors, which affect its production and
excretion, as well as those that impact its measurement and,
therefore, is unreliable in patients with severe liver dysfunction including ACLF. The AKI criteria seem more relevant
as they rely on a dynamic change rather than a static measurement of serum creatinine. A lower value of serum creatinine is more relevant in patients with ACLF. Serum creatinine above 0.7 mg/dl (as derived from the AARC score) has
a sensitivity of 78% and specificity of 36% for prediction of
30-day mortality in patients with ACLF. For the diagnosis
of kidney failure, the conventional cutoff of 1.5 mg/dl even
though had a low sensitivity of 48% but had a specificity
of 99.8% for 30-day mortality. Kidney failure (serum creatinine ≥ 1.5 mg/dl) was seen in 22% of ACLF patients at
baseline and developed in another 30% within a month. The
majority of patients of ACLF developed new episodes of
AKI in the first 2 weeks (11%). Further, the KDIGO definition for AKI (incorporating the urine output criteria) has
been shown to be more accurate in determining AKI course
in critically ill cirrhotics; however, this needs to be evaluated
for patients with ACLF [110].
Apart from the severity, the course of AKI was seen to
be an important predictor of clinical outcomes. Almost 80%
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of the patients, who did not present with AKI at baseline or
developed within the first 7 days, survived 1 month. However, in patients who presented with AKI, resolution of AKI
was associated with a better survival. Progression of AKI
was associated with highest mortality of 75%. Development
of new AKI as well as non-resolution or persistence of AKI
was associated with almost 50% mortality at 1 month in
patients with ACLF [109].
Kidney injury biomarkers have been studied in patients
with decompensated cirrhosis; however, their utility in diagnosing, staging and understanding the spectrum of AKI
including the response to therapies has not been carefully
evaluated in patients with ACLF. There is a potential to look
at the role of biomarkers of tubular damage, namely N-GAL,
Kim-1, IL-18 and l-FABP to differentiate functional AKI
or HRS from structural AKI, i.e., ATN patients with ACLF
[111] as ATN or structural kidney damage may necessitate
the need of simultaneous liver–kidney transplant as against
liver transplant alone for HRS [112].
Treatment for AKI in ACLF depends on the etiology,
severity, complications, and the presence of other organ failure and/or hemodynamic status. Targeting the components
of PIRO, i.e., combating systemic inflammation with antiinflammatory strategies (for instance intravenous albumin,
N-Acetylcysteine), bilirubin reduction, avoidance of nephrotoxic drugs, aggressive management of circulatory failure
and maintaining a high mean arterial pressure may prevent
AKI development and progression in patients with ACLF.
Albumin intravenous administration has multiple benefits
volume correction in addition to its anti-inflammatory and
immunomodulatory properties.
Data on use of vasoconstrictors for AKI in ACLF are
limited. Terlipressin given as an infusion is superior to
noradrenaline in the management of HRS-AKI in patients
with ACLF, but needs extra precaution and close monitoring
for terlipressin-related adverse effects [111]. The response
to vasoconstrictor drug is multifactorial and depends on the
severity of AKI, MELD score and AARC grade [113, 114].
Response to vasoconstrictors in AKI in ACLF patients is
partial and seen in only in about a third of patients. There is,
therefore, quite often a need for renal replacement therapy
(RRT). The indications for RRT include severe volume overload, hyperkalemia, hyponatremia and worsening metabolic
acidosis not responding to conservative management [115].
Unlike other indications, the threshold for initiating RRT
should be relatively low, i.e., when AKI occurs as part of
multi-organ failure or in non-oliguric patients, if the daily
fluid balance cannot be maintained, Continuous Renal
Replacement Therapy [CRRT] should be considered [116].
The mode of dialysis, i.e., hemodialysis (HD), Slow Low
Efficient Dialysis (SLED) or CRRT should be chosen based
on the hemodynamic status of the patient and the expertise
and availability of the equipment [115, 116].
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Recommendations
	5.1.	Renal failure in ACLF.
	5.1.1.	Defining AKI in ACLF.
	5.1.1.1.	AKI criteria (defined as an absolute increase in
serum creatinine of 0.3 mg/dl within 48 h or by percentage increase in serum creatinine of more than
50% from baseline, which is known, or presumed,
to have occurred within the previous 7 days) should
be used for the diagnosis of AKI in patients with
ACLF [1, A].
	5.1.1.2.	AKIN criteria should be used for the diagnosis and
prognostication of AKI in ACLF patients (1, B).
	5.1.1.3.	Urine output should be considered to assess the
stage and course of AKI in patients with ACLF
admitted to the ICU [2, C].
	5.1.1.4.	In the absence of baseline serum creatinine, AKI
should be diagnosed based on the cutoff value of
serum creatinine. A cutoff value of 1.1 mg/dl is
a reliable marker of significant renal dysfunction
and 1.5 mg/dl of kidney failure in patients with
ACLF [1, B].
	5.1.2.	Course of renal failure in ACLF.
	5.1.2.1.	AKI is more common and rapidly progressive in
patients with ACLF as compared to decompensated
cirrhosis and is associated with significantly worse
outcome (1, B).
	5.1.2.2.	Patients with ACLF and AKI have high 30-day
mortality. The course of AKI is an important determinant of clinical outcomes [1, A].
	5.1.2.3.	Progression of AKI has the worst outcome and
at the same time resolution is associated with
improved survival. Both persistence and new development of AKI are associated with a high shortterm mortality in patients with ACLF [1, B].
	5.1.2.4.	Serum creatinine levels 1.1–1.5 mg/dl or AKIN
I are also associated with significant mortality in
ACLF patients (2, B).
	5.1.3.	Treatment of renal failure in ACLF.
	5.1.3.1.	All attempts should be made to prevent development of new AKI in patients with ACLF [1, C].
	5.1.3.2.	Patients with ACLF should be stratified based on
the PIRO (Predisposition, Infection/Inflammation,
Response, Organ failure) score for identifying
patients at risk of AKI development [1, B].
	5.1.3.3.	Targeting the components of PIRO, i.e., combating systemic inflammation with anti-inflammatory strategies (for instance intravenous albumin,
N-Acetylcysteine), bilirubin reduction, avoidance
of nephrotoxic drugs, aggressive management of
circulatory failure and maintaining a high mean

13

372

arterial pressure may prevent AKI development
and progression in patients with ACLF [2, C].
	5.1.3.4.	Data on use of vasoconstrictors for AKI in ACLF
are limited. Terlipressin given as an infusion is
superior to noradrenaline in the management of
HRS-AKI in patients with ACLF (B1). Terlipressin use in ACLF should be carefully monitored for
adverse effects (1, A).
	5.1.3.5.	Severity of AKI, MELD score and ACLF grade
predicts therapeutic response to terlipressin and
albumin in patients with HRS-AKI in ACLF (1, B).
	5.1.3.6.	New treatments should be explored for patients
with AKI-ACLF looking at systemic inflammation
as a potential target (2, A).
	5.1.3.7.	Patients with ACLF with AKI persistence should be
considered for additional pharmacologic interventions to prevent AKI progression and enhance AKI
resolution [2, C].
	5.1.3.8.	Initiate RRT emergently when life-threatening
changes in volume overload, hyperkalemia, hypernatremia and worsening metabolic acidosis not
responding to conservative management (1, C).
The threshold for initiating RRT should be lowered
when AKI occurs as part of multi-organ failure (1,
C), or in non-oliguric patients if the daily fluid balance cannot be maintained.
	5.1.3.9.	Biomarkers of tubular damage, urine NGAL and
IL-18 need to be evaluated for a role in patients
with ACLF to determine the need for early RRT or
artificial liver support (2, C).
Hepatic encephalopathy
The development of HE within 4 weeks of onset of jaundice
is part of the criteria for defining acute-on-chronic liver failure (ACLF) [1, 2]. In the recent AARC data, HE was seen to
be present in about 40% of the patients. Multiple prospective and retrospective studies had shown that HE in ACLF
patients is associated with higher mortality, especially in
those with grade III–IV encephalopathy, similar to that of
acute liver failure (ALF). The experts proposed and defined
cerebral dysfunction and cerebral failure as the presence of
grade I and II HE and Grade III and IV HE, respectively.
The presence of HE itself increases short-term mortality in
ACLF as is the severity, i.e., grade of HE [3].
The pathophysiology of HE is complex, and impairment
of brain energy and development of brain edema appear to
be central in the pathogenesis of encephalopathy [117, 118].
Inflammation plays a greater role in the pathogenesis of HE
in patients with ACLF than in patients without ACLF and
is associated with a cytokine storm. Recent data also suggest that neuro-inflammation may have a significant role in
brain disturbance [117]. Cerebral edema has been observed
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in ACLF, and even low cerebral edema can be detected by
proper CT and MRI. Vasogenic cerebral edema as detected
by advanced MRI techniques like magnetization transfer
ratio (MTR), diffusion tensor imaging (DTI) and diffusion
weighted imaging (DWI) is common, but rarely requires
specific treatment [118]. Using advanced MRI techniques,
Gupta et al. demonstrated presence of cerebral edema
increases with severity of ACLF. Correlation between mean
diffusivity (MD) values and IL-6 levels suggest pathogenic
role of inflammation in cerebral edema. MELD score and
MD values in frontal white matter have prognostic significance in ACLF [118]. Ammonia, systemic inflammation and
oxidative stress are key factors in the pathogenesis of HE,
which may be modulated by glutaminase gene alteration or
by the presence of spontaneous shunts [118].
Management of HE in hospitalized patients requires
admission to the ICU and includes—(1) identification and
treatment of precipitating factors, including infections and
(2) specific measures for decreasing hyperammonemia
and systemic inflammation. High volume plasmapheresis
or albumin dialysis and identification and embolization of
portosystemic shunts may be required in refractory patients.
Recently analyzed AARC data showed that ammonia was
significantly and persistently high in patients with grade III
and IV HE (p < 0.001). l-Ornithine l-Aspartate (LOLA)
for Hepatic Encephalopathy has a conflicting role as far as
HE and ammonia reduction in patients of cirrhosis is concerned. Few recent meta-analysis showed a positive role of
LOLA in reduction of ammonia as well as improvement in
encephalopathy. Hence, LOLA can be considered as a potentially beneficial therapy for ACLF patients with HE and/
or hyperammonemia [119]. However, a large prospective
study would be needed. Emerging therapies include therapy
for circulatory dysfunction and correction of hyponatremia
[120].
Ammonia is a simple surrogate marker for HE in ACLF
and correlates with severity of HE/cerebral failure. In the
large AARC database, arterial ammonia levels were analyzed with respect to disease severity and outcome. At
baseline, ammonia was significantly high in patients with
cerebral dysfunction (HE grade I–II) and cerebral failure
(HE grade III–IV). The patients who showed improvement
in HE grades at day 4 and day 7 showed significant reduction in plasma ammonia level [121]. Dynamic change in
ammonia level correlates well with clinical course of HE.
However, ammonia-targeted therapy needs further trials and
validation.
Recommendations
	5.2.	Hepatic encephalopathy in ACLF.
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	5.2.1.	HE, including grade 1-2 HE (organ dysfunction)
and grade 3-4 HE (organ failure), is present in
about a third of the ACLF patients (2, B).
	5.2.2.	HE with all grades of severity and independent of
other organ failures is associated with increased
mortality; the mortality is higher in grade 3–4
(organ failure) compared with grade 1–2 HE (organ
dysfunction) [1, B].
	5.2.3.	Inflammation plays a major role in the pathogenesis
of HE in patients with ACLF and is associated with
cytokine storm [1, B].
	5.2.4.	Management of HE in hospitalized patients requires
admission to the high dependency or intensive care
unit and includes—(1) identification and treatment
of precipitating factors, including infections, and
(2) specific measures for decreasing hyperammonemia and systemic inflammation. Large volume plasmapheresis or albumin dialysis and identification
and embolization of portosystemic shunts may be
required in refractory patients [1, C].
	5.2.5.	Ammonia is a simple surrogate marker for HE in
ACLF and correlates with severity of HE/cerebral
failure [2, B].
	5.2.6.	Dynamic change in ammonia level correlates well
with clinical course of HE [2, B].
	5.2.7.	Ammonia-targeted therapy needs further trials and
validation [2, B].
	5.2.8.	Lactulose, rifaximin, NH3-lowering strategies
remain the main therapy for HE in patients with
cirrhosis (1, B).
Coagulation in ACLF
In ACLF, alterations in primary and secondary hemostasis
result in rebalanced coagulation, which leads to either bleeding or thrombotic episodes [122–125]. In addition, organ
failures in ACLF may further disturb cirrhotic hemostatic
imbalance. These include circulatory dysfunction [123], systemic inflammatory response syndrome [124, 125], sepsis,
endogenous heparin-like substances or heparinoids [126]
and renal dysfunction [127, 128].
Coagulation system in liver diseases is usually assessed
by INR and platelet counts. Study by Premkumar et al. [129]
and Blasi et al. [130] suggests that the ACLF is a hypocoagulable and hypofibrinolytic disorder and development of SIRS
[131, 132] and sepsis further increases the hypocoagulability
in these patients with increased chances of coagulopathic
bleeding. Indirect evidence suggests that the endogenous
heparinoids in ACLF patients with SIRS and sepsis could
induce increased hypocoagulable state [130]. Conventional
tests are insensitive to assess the complex coagulopathy in
ACLF can be further complicated by SIRS and sepsis. The
development of SIRS by day 7 further increases the INR
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(p < 0.001); however, no effect on platelets has been noted.
ACLF cases with sepsis at presentation show increased INR
and low platelets. Studies indicate the decline of platelets in
first week associated with increased chances of organ failure
and short-term mortality [131]. Acute variceal bleed at the
time of presentation did not have association with baseline
platelet counts; however, the INR was significantly higher in
bleeders than non-bleeders in the recently analyzed AARC
data.
PT-INR or prothrombin times is useful for prognostication, but are insensitive for detection of coagulopathy. More
evidence-based algorithmic approach is needed for diagnosis
and management of ACLF-induced coagulopathy.
Recommendations
	5.3.	Coagulation in ACLF.
	5.3.1.	ACLF is a hypocoagulable state and this can get
escalated with the development of SIRS and sepsis
[2, C].
	5.3.2.	Traditional coagulation measures, including prothrombin time (PT), activated partial thromboplastin time (aPTT), international normalized ratio
(INR), fibrinogen levels and bleeding time (BT) do
not measure bleeding risk in ACLF [2, B].
	5.3.3.	Coagulopathy assessment and management in
ACLF should be guided based on global coagulation assessment system [ROTEM/TEG/SONOCLOT] [2, C].
	5.3.4.	Patients need to be characterized as bleeding or
thrombosis phenotype by clinical assessment of
major bleeding and d-dimer assay, respectively
[2, C].
	5 .3.5.	Global viscoelastic tests (TEG/Sonoclot/
ROTEM) provide a more physiologic assessment of coagulation and should be considered
to guide blood transfusion requirements in liver
transplantation [1A] and other major surgery
[2B] and invasive procedures [2C]. Application
of global viscoelastic testing with ACLF in the
ICU setting requires more data [2C].
Portal and systemic hemodynamics in ACLF and variceal
bleed
Portal hypertension in liver disease is associated with both
structural damage, which is the irreversible component, and
dynamic component that includes increase in cytokine production, endothelial dysfunction, impaired vasorelaxation,
and impaired vascular relaxation, which may be reversible
component in the pathophysiology of portal hypertension
after recovery. Thus, increased portal pressure in ACLF not
only contributes to variceal bleeding but also to development
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of rapid onset ascites and other systemic complications
including organ failures of ACLF. Majority of the patients
with ACLF die during the first 45 days (median time to death
15 days) since the diagnosis [132]. ACLF patients have been
shown to have much higher HVPG as compared to compensated cirrhotics. Among survivors of ACLF, complications such as ascites, coagulopathy gradually regress by 3
months [133]. It is thus likely that in patients with ACLF,
the portal pressure gets acutely elevated and, after recovery,
hepatic inflammation and cytokine levels decrease, which
leads to improvement in hepatic as well as systemic hemodynamics. This was also indicated in a recent Asia Pacific
multi-center study that higher cardiac output correlated with
30-day mortality (p < 0.019) and higher HVPG was associated with increased risk of variceal hemorrhage and mortality at 30 (p < 0.02) and 90 days (p < 0.001) [133]. Notably,
these features were more pronounced in alcoholic hepatitis
patients [134]. Choudhury et al. showed that baseline HVPG
and mean pulmonary artery pressure were independent predictors of three-month mortality in ACLF [135].
Variceal progression and role of pharmacotherapy
in ACLF The rapid development of varices and bleeding is
a matter of great concern in ACLF patients. It is important
to determine the need of acute portal pressure reduction in
these patients. It is likely that the patients would benefit
from portal hypertension-reducing drugs like beta-blockers,
especially in the acute phase of portal hypertension. NSBB
have beneficial effects on the severity of portal hypertension, which requires both the beta-1 and beta-2 actions of
the drug to ameliorate splanchnic vasodilation and high cardiac output.
Patients on NSBB had less severe grade of ACLF and
a slower progression of ACLF during the study period.
Patients who were receiving NSBBs in the previous
3 months and discontinued NSBBs (n = 78) after development of ACLF had a higher mortality (37% vs. 13%) and the
main difference between those who discontinued or did not
discontinue BB was the presence of circulatory dysfunction
(hypotension requiring pressers) and respiratory failure. In
another RCT comparing carvedilol with placebo in patients
with ACLF (defined by APASL criteria) with either no or
small esophageal varices and no contraindication to carvedilol use, carvedilol was found to reduce mortality, development of SBP and AKI at week 4 [135]. Thus, it is clear that
patients should be continued on NSBBs, if feasible, even if
ACLF develops [136].
Regarding the safety and radiation exposure of technical
procedures for hepatic hemodynamics, Hari et al. studied the
safety profile of HVPG measurement prospectively [137].
Accordingly, HVPG procedure showed a good safety profile
and the radiation exposure was in most of the cases low.
However, the HVPG measurement is invasive and difficult
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for routine clinical practice. Therefore, non-invasive surrogates that correlate well with invasive HVPG measurements
are urgently needed in patients with ACLF [137–139].
PICD incidence, presentation, diagnosis and management
in ACLF Ascites is one of the syndrome defining components and in the AARC study, about 91% patients had
ascites at presentation. About one-third of the patients presenting with ACLF do require paracentesis for severe grade
ascites [140]. The presence of ascites in ACLF is different
in many aspects from decompensated cirrhosis or AD [141].
Development of PICD in ACLF is associated with very high
mortality. Albumin infusion was shown to significantly
reduce mortality. Albumin infusion also helped in reducing
to nearly half the incidence of development of new complications such as hyponatremia, hepatic encephalopathy
and acute kidney injury. A high PRA level in ACLF patient
reflects state of severe systemic inflammation, high portal
pressure and systemic circulatory dysfunction [142, 143].
All precautions and monitoring including plasma renin
activity are needed in undertaking ascetic tap in ACLF
patients. Ascites in ACLF is part of acute portal hypertension and large volume paracentesis significantly alters the
hemodynamics. Pharmacological agents, such as use of
vasoconstrictors, should be studied to reduce the incidence
of PICD in ACLF patients.
Recommendations
	5.4.1.	Systemic, hepatic and pulmonary hemodynamics in
ACLF.
	5.4.1.1.	Baseline HVPG is an important predictor of mortality in ACLF (2, B).
	5.4.1.2.	The reduction in HVPG significantly influences the
management of ACLF (2, C).
	5.4.1.3.	The safety and standardized procedure of HVPG
measurement should be emphasized. Non-invasive
surrogates of HVPG need to be investigated in
ACLF (1, C).
	5.4.2.	Variceal progression in ACLF and role of preemptive BB therapy.
	5.4.2.1.	Increased portal pressure in ACLF can not only
contribute to variceal bleeding but also other systemic complications and organ failures in ACLF
[1, A].
	5.4.2.2.	NSBBs may reduce systemic inflammation and may
have beneficial effects in ACLF patients over and
above their portal hemodynamic effects [2, A].
	5.4.2.3.	ACLF patients should be started or continued on
NSBBs, if there are no contraindications [2, B].
	5.4.3.	PICD incidence, presentation, diagnosis and management.
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	5.4.3.1.	P ICD is a result of significant derangement of
systemic and splanchnic hemodynamics with
a decrease in effective arterial blood volume,
which is triggered by large volume paracentesis
(> 5 L) [1, A].
	5.4.3.2.	PICD occurs in about 80% of ACLF patients when
a large volume paracentesis is performed without
additional therapeutic management. However, the
incidence is reduced when volume expansion with
albumin is used [1, A].
	5.4.3.3.	Terlipressin, a vasopressin analog, is partially effective and has been shown to have a synergistic effect
with albumin in preventing PICD [1, B].
	5.4.3.4.	Non-selective β-blockers, such as propranolol,
have been suggested to increase the risk of PICD
and mortality in cirrhotic patients with refractory ascites. There is lack of data in patients
with ACLF [2, B].

Prognostic models and disease severity scores
for ACLF
Prognostic models and disease severity scores
The disease severity assessment is needed for prognostication and to guide the therapy [144–146]. Disease severity
scores such as model for end-stage liver disease (MELD)
have been considered for organ allocation. However, MELD
score does not take into account cerebral, circulatory and/or
respiratory failures, thus giving no priority to patients with
ACLF [147]. The various ICU scores like Sequential Organ
Failure Assessment (SOFA), Acute Physiology and Chronic
Health Evaluation (APACHE II) have also been evaluated
for ACLF patients [147]. A study by Garg et al. in 2012 from
New Delhi showed the predictability of these scores and also
the relevance of one, two or more organ failures [28]. Subsequently, CLIF consortium has developed CLIF-SOFA score
for assessing disease severity and prognostication in ACLF
[11]. We had earlier shown that patients of ACLF have a
high mortality in the presence of HE and hyponatremia
in addition to high MELD, APACHE II and SOFA scores
[28], necessitating inclusion of these parameters. A clinical
event like HE or the laboratory parameters like bilirubin,
creatinine, INR, serum sodium, plasma lactate or the liver
histopathology reports and various disease severity scores
do give near accurate prognostication.
Furthermore, the available prediction scores have been
validated at baseline, but none has been evaluated in a
dynamic manner for prognostication in ACLF patients.
The severity of ACLF, rapid progression, development of
sepsis and subsequent multi-organ failure (MOF), poor outcome with liver transplantation at the onset of MOF needs
dynamic monitoring. Recent studies support for developing
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a dynamic model that could predict the outcome and appropriate time for LT. Chan et al. [147] in 149 patients showed
that APACHE II scores ≥ 12 and MELD scores ≥ 28 after
the first week of treatment were independent predictors of
mortality. Mathurion et al. [148] showed that in the absence
of response to corticosteroid for AH as assessed by Lille
score on day 7 and consideration of early LT lead to significant cumulative 6-month survival rate (77 ± 8% vs. 23 ± 8%,
p < 0.001). In large UK and US cohort of severe autoimmune
hepatitis showed that not the baseline MELD/UKELD but
the use of corticosteroid and no improvement in MELD/
UKELD scores within 7 days had a poor outcome and suggested early consideration of other strategies including liver
transplant [149–152]. A dynamic model that could predict
the reversibility or need for liver transplant is urgently
required. Early prediction of transplant-free survival, decision for transplant before onset of sepsis or multi-organ failure and prioritization for liver transplant could help improve
the outcome of these patients.
Organ dysfunction and organ failure in ACLF for early risk
stratification
The CLIF-SOFA and the CLIF-OF (Organ Failure) scoring and the cutoff were developed arbitrarily and included
patients with hepatic and non-hepatic insults [11]. The
organ failure was solely derived based on a consensus opinion by the experts [11]. The score is a bit cumbersome and
becomes predictive of mortality only when extrahepatic
organ failures are included. Earlier studies [28] and a recent
study [152] showed that a simple score considering only
the number of organ failures is easier to recall in predicting mortality in ACLF patients. The recently established
and evaluated TPPM model in HBV ACLF patients from a
single center large cohort, which displayed a superior predictive ability when compared with MELD and MELD-Na
models [n-153]. TPPMs used TBIL, INR, HBV DNA and
complications as parameters [153, 154]. Based on current
multinational cohort, TPPMs demonstrated superiority to
CLIF-C OFs, CLIF-C ACLFs, MELDs and MELD-Na in
predicting 28-day and 90-day mortality in cirrhotic HBVACLF patients [155].
The AARC score, as mentioned above, provides a
physician a window to decide early and explore definitive therapies including liver transplantation (Table 4). A
patient in whom the AARC score increases from 5 or 6 to
11 and above (change in grade of liver failure from I to III)
at day 4 and day 7 increases the mortality significantly and
a need for emergent transplantation in patients who fulfill
the criteria. At the same time, the persistence of grade I
or II liver failure till day 7 predicts improved survival,
and a possibility of conservative treatment to be effective
[3] (Fig. 4). AARC score has been compared with other
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scores for assessing the severity of ACLF such as SOFA,
CLIF-SOFA, and MELD. The AARC score has been found
to be superior to the other scores [3] (Fig. 5).
Recommendations
	6.0.		Prognostic models and disease severity scores
for ACLF.
	6.1.		AARC score and other prognostic models.
	6.1.1.	AARC score is a very good prognostic model for
the severity assessment and has been adequately
validated. It has been proven to be superior to
MELD/MELD Na., CLIF-SOFA and SOFA scores
for patients with ACLF [2, A].
	6.1.2.	The cumulative mortality increases with rise in
AARC score in the first week in Grade I (5–7), II
(8–10) and III (11–15), respectively [2, A].
	6.1.3.	Treatment recommendations for ACLF should be
based on AARC score. A trend of AARC score
within first week can predict the need of liver transplant. Score of < 10 at presentation or decrease in
score below 10 by the end of first week is associated with higher chance of survival [1, B].
	6.1.4.	Patients with AARC Score > 10 should be listed
for LT. Transplant evaluation based on the AARC
score needs prospective studies [2, B].
	6.1.5.	AARC-ACLF score be estimated at admission in
patients diagnosed to have ACLF as per AARCACLF definition [1, B].
	6.1.6.	AARC-ACLF score should also be estimated on
Day 4 and Day 7 to predict the course of illness and
prognosis [2, A].
	6.1.7.	The TPPM model has a superior predictive value
for HBV ACLF outcomes than MELD and CLIFFSOFA models (2, C).

	6.1.8.	AARC score holds good in predicting the outcome
in critically ill ACLF patients [1, C]).
	6.1.9.	Lactate should be used for defining the severity of
the ACLF syndrome. Lactate clearance compared
to baseline lactate is a better indicator of patient
status [1, C].
	6.1.10.	There is limited role of Renal Replacement Therapy
(RRT) & Extra Corporeal Liver Support System
(ECLS) to treat hyperlactetemia [2, B].
	6.2.		Organ dysfunction and organ failure in ACLF for
early risk stratification.
	6.2.1.	Organ dysfunction and failure should not be used
in the definition, but for prognostication in patients
with ACLF [1, A].
	6.2.2.	Liver failure should be defined by a combination of
bilirubin and INR and should be classified as mild/
moderate and severe based on AARC as all patients
have liver failure [1, B].
	6.2.3.	Liver, kidney and brain remain organs of utility in
patients with ACLF [1, B].
	6.2.4.	Organ dysfunction and failure for brain should be
based on AARC score [1, C].
	6.2.4.	Respiratory and circulatory failure may be considered as organs of futility in patients with ACLF
which may contraindicate liver transplant [1, C].
	6.2.5.	For the diagnosis of organ dysfunction for kidneys
in patients with ACLF as for patients with cirrhosis, AKIN criteria should be used [1, A].
	6.2.6.	Kidney failure should be defined based on serum
creatinine above 1.5 mg/dl as per the AARC score
[2, B].
	6.2.7.	The mortality in ACLF increases with the number
of organ failures (1, C).

Table 4  AARC score and ACLF grade
AARC score
Points

Total Bilirubin (mg/dl)

1
< 15
2
15–25
3
> 25
Minimum-5, Maximum-15

HE Grade

PT-INR

Lactate (mmol/l)

Creatinine (mg/dl)

0
I–II
III–IV

< 1.8
1.8–2.5
> 2.50

< 1.5
1.5–2.5
> 2.5

< 0.7
0.7–1.5
> 1.5

AARC-ACLF grade
Grade

Score

I
II
III

5–7
8–10
11–15
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Fig. 4  Algorithm for management of ACLF. The algorithmic
approach to ACLF is highlighted based on the severity of liver failure, acute etiology and specific therapy and dynamic disease course.
The specific treatment initiated, but if the disease severity is more,
i.e., AARC Score (consideration of bilirubin, creatinine, INR, lactate
and HE grade) 11 or more the response is poor with best medical supportive car; hence, early consideration for liver transplant should be

done, whereas other group needs to be seen for 4–7 days with specific
therapy and standard medical therapy. Any deterioration or AARC
score 11 or more needs to consider LT. The presence of extrahepatic
organ failure needs to be managed, and optimization and improvement need to be correlated with over all recovery else poor prognoses
to be considered

Treatment of ACLF

	7.1.1		Nucleos(t)ide analogs should be started immediately in all HBV-infected patients at presentation
while waiting for confirmation by HBV DNA level.
Potent antiviral drugs, such as tenofovir, tenofovir
alafenamide or entecavir, should be used [2,B].
	7.1.2.	Assessment of reduction of HBV DNA level at day
15 after nucleos(t)ide analogs is encouraged; if < 2
log reduction, it suggests poor prognosis (2, B).

Antiviral strategies in ACLF HBV reactivation
The presence of high HBV DNA [> 10(5) copies/ml/
or > 2 × 10 (4) IU/ml] is highly sensitive and specific for
the diagnosis [152]. Early and rapid reduction of HBV
DNA is the essence of therapy [153]. Several studies have
indicated that if the reduction in DNA of > 2 logs could be
achieved within 2 weeks, the survival could be improved.
This could be related to suppression of hepatocellular
necrosis and cytokine release [154].
Besides patients who present with ACLF, it is worthwhile that prophylactic therapy should be considered for
HBsAg-positive patients undergoing chemotherapy [155].
There are insufficient data to recommend antiviral therapy
for HBsAg-negative and anti-HBc-positive patients with
possible reactivation of occult HBV infection [156, 157].
Recommendations
	7.1.		Antiviral strategies in ACLF HBV reactivation.

.

Liver transplantation
A characteristic feature of ACLF is its rapid progression, the
requirement for multiple organ support and a high incidence
of short- and medium-term mortality of 50–90%. The 28-day
mortality rate was 15 times higher in patients with ACLF
as compared to other chronic liver disease (CLD) patients
[1–11, 158]. Patients with ACLF are susceptible to infection
and early transplant-free survival is very low [159, 160].
Patients who develop infectious complications (particularly
pneumonia and/or sepsis) and patients who receive renal
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AARC Score vs. CLIF-C

0.80(0.75-0.85) vs. 0.75(0.69-0.80),
p <0.001

AARC vs. SOFA

0.80(0.75-0.85) vs. 0.72(0.66-0.78),
p <0.001

AARC Score vs. MELD

0.80(0.75-0.85) vs. 0.76(0.70-0.81),
p <0.001

AARC Score vs. APACHE

0.80(0.75-0.85) vs. 0.69(0.63-0.72),
p <0.001
Disease
severity
score
S
AARC core

AUROC

Cut off

Sensitivity

Specificity

0.804

10.5

71.9

77.5

MELD

0.763

30.9

63.5

75.2

63.2

75.4

CLIF

0.750

12.5

48.1

79.2

69.1

61.2

S
OFA

Positive
predictive
value
66.8

Negative
predictive
value
77.2

SOFA

0.728

9.5

63.8

69.5

62.2

70.9

APACHE II

0.692

15.5

57.9

68.5

56.8

69.8

CTP

0.657

11.5

68.5

55

50.4

74.9

Fig. 5  Comparison of AARC score against other disease severity score

replacement therapy or mechanical ventilation are less likely
to undergo liver transplantation. Established sepsis/MODS
precludes transplant and is associated with poor outcome.
Both deceased and living donor transplants are viable and
very useful options with very good results [161]. Liver transplant survival has been shown to be above 90% in patients
with HBV reactivation [162].
Most important aspect in managing this group of sick
patients is to decide the time frame and an algorithm. If
the patient is too sick from the beginning and needs early
LT without waiting for spontaneous recovery, this should
be decided soon enough. On the other hand, patients who
are salvageable and need time for recovery should be monitored closely in a time frame before deterioration so that they
either recover or can undergo LT at an appropriate time. The
third group is of those who need bridge therapy observed
while on supportive care and bridging therapy, to define nonresponse and emergency LT or for transplant-free survival.
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Every ACLF patient at admission needs to be assessed
for disease severity score, presence of SIRS with or without
sepsis, HE and number of organ dysfunction/failure. The
baseline MELD > 28, AARC Score > 10, advanced HE in
the absence of overt sepsis or multi-organ failure can be
considered for early LT [3]. In the absence of LT option,
these patients can be offered early bridge therapies in the
form of therapeutic plasma exchange and liver dialysis and
the response could be evaluated by end of first week and the
possibility of being listed for LT or awaiting spontaneous
recovery [3, 163]. The maximum recovery from organ failure, resolution of sepsis and eligibility for LT was observed
in the first week [3]. The SIRS and/or sepsis and development of AKI occur by days 7–15; hence, the interventions
like prophylactic antibiotics, periodic septic screening with
the help of biomarkers and avoidance of nephrotixic drugs
were needed [77].
ACLF is characterized by rapid downhill course
with extrahepatic organ failure and high short- and
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medium-term mortality ranging from 34 to 51% [1].
Although many prediction models of early transplantation
listing exist, none reliably predicts chances of reversibility
of ACLF. A recent study showed that the ACLF patients
develop SIRS and sepsis within 7 days of hospitalization
[77]. Lin et al. [164] and Pamecha et al. [165] proposed
serial assessment of these groups of patients in the first
week of hospitalization for prioritization for liver transplantation. However, being sick, often critically ill and
admitted to ICUs, rapid progression of liver failure and
onset of multi-organ failure, transplantation was feasible
in ~ 25% of patients [165]. Recently, a study showed that
the LT waiting list mortality in ACLF patients is around
67% and is predominantly due to sepsis, respiratory failure
with mechanical ventilation, high vasopressor requirement
and need of RRT [165]. Though objective criteria were
not used to define eligibility for LT, patient characteristics
that were reported to consider an ACLF patient unfit were
(1) sepsis with 2 or more organ failures or uncontrolled
sepsis [166], (2) advanced azotemia, i.e., serum creatinine > 4 mg/dl or increase in creatinine by 300% from
baseline or the need of Renal Replacement of therapy
[167], (3) Respiratory failure [severe ARDS defined by a
P/F ratio < 150] or HE requiring ventilator support > 72 h
[168] (4) 4 or more organ failures anytime, (5) active gastrointestinal bleeding, and/or (6) hemodynamic instability
requiring > 3 mg/h noradrenaline [169].
On the other hand, in the absence of liver transplantation, the outcome is dismal. In fact, liver transplant is potentially the only curative treatment option with good outcome,
irrespective of etiology in this cohort. An analysis of 1021
patients from AARC cohort suggested MELD or MELD
with HE is a good prediction model for making decision
for LT. A patient with MELD > 27 needs listing, a score of
30 or above with presence of encephalopathy or new onset
HE, bilirubin of > 22 mg/dl with INR > 2.5 and grade III-IV
HE is associated with 80% mortality within 28 days and
persistence of the same till day 4 is associated with mortality close to 100%. Hence, these patients need emergent LT
either at baseline or upon no improvement within day 4–7 of
hospitalization [163]. So first week of presentation in ACLF
is crucial [77, 170]. This concept is supported by a window
of 1 to 2 weeks, i.e., being sick and with no improvement by
supportive care [171].
Disease severity scores such as MELD have been considered to determine organ allocation. This disease severity
score has not taken into consideration of cerebral, circulatory and respiratory failure and does not offer any priority despite being sick [172, 173]. The recently published
dynamic AARC model consisting of bilirubin, creatinine,
INR, grade of hepatic encephalopathy and plasma lactate is
a reliable model to predict the outcome at each time point,
hence, the need of LT can be considered for prioritizing
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LT but further studies needed on this [3]. Emergency LT,
promotion of live donor transplant and allocation priority
in deceased donor setting needs consensus and further large
size studies [77, 163, 170–176].
Sometimes, patients with ACLF have rapidly worsening
liver and renal functions, needing quick decisions based on
renal dysfunction. There is paucity of data on simultaneous
liver and kidney transplant in this subset of ACLF patients
[112].
Recommendations
	7.2.	Liver transplantation.
	7.2.1.	No validated criteria and scoring system for early
and correct identification of patients with ACLF
who would benefit from early liver transplantation [2, A].
	7.2.2.	LT should be offered early in the course of
ACLF. When indicated, early liver transplantation avoids complications of sepsis and multiorgan failure [1, B].
	7.2.3.	SIRS, sepsis, HE, liver failure, extrahepatic organ
dysfunction/organ failure are important prognostic
factors [2, A].
	7.2.4.	Organ failure per se should not be a contraindication for liver transplantation, except if cardiac
or pulmonary support is needed or there is rapidly
progressive organ failure at day 4 or 7 [2, C].
	7.2.5.	APASL AARC model seems to be better in patient
selection for liver transplantation as it enrolls
patients early enough, before organ failure. However, the AARC score needs to be validated in large
and varied populations and also its capability to
predict post LT outcome [2, B].
	7.2.6.	Patients with HBV reactivation with intermediate MELD should be assessed for early transplant
if cirrhosis, bilirubin > 10 mg/dL, PT < 40% and
platelet < 100 × 109/L [2, C].
	7.2.7.	Steroid ineligible patients with severe alcoholic
hepatitis should be listed on priority for liver transplant. Selective use of liver transplantation can be
lifesaving for medically refractory alcoholic hepatitis [1, A].
	7.2.8.	Liver transplantation should be reserved for severe
alcoholic hepatitis patients with low risk of recidivism as assessed by a formal psychosocial evaluation [1, A].
	7.2.9.	Transplant evaluation can be started based on liver
specific dynamic scores by the end of first week of
medical treatment or earlier [2, B].
	7.2.10.	Allocation of cadaveric livers should depend on
maturity of cadaveric program in the country [2,
C].
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	7.2.11.	Patients with advanced ACLF also have good outcome after LT [1, A].
Liver dialysis and emerging therapies in ACLF
The hepatocellular injury in ACLF is driven to a large extent
by a “cytokine burst”, with elevated levels of multitude of
cytokines, small molecular weight toxins, and vasoactive
substances which are known to accumulate secondary to the
failing liver [122]. There is an additional challenge of the
injury due to endotoxin and metabolites released from gut
bacteria. These toxins not only potentiate the hepatic injury
but also deprive the liver of an environment, which is conducive for regeneration. The released toxins are responsible
for the systemic inflammation, loss of adaptive and innate
immunity and cause vital organ dysfunction, which affects
all the major organs [174].
Extracorporeal liver support therapies are used to bridge
the liver until recovery or liver transplantation in patients
with ALF and ACLF. Various randomized controlled trials in patients with ACLF have shown improvement in HE,
hepatorenal syndrome, circulatory dysfunction and immune
dysfunction without improvement in transplant-free survival
[175–182]. In the most recent meta-analysis and systematic
review, no benefit of MARS treatment in reducing mortality as compared to SMT was noted [182]. Even though
both these meta-analysis have the limitations of enrolling a
heterogenous group of patients. However, contrary results
were shown by systematic review by Kjaergard et al. where
it was seen that ALS reduced mortality by 33% in patients
with ACLF as compared to SMT [183, 184]. More recently,
studies have shown that ALS could be an effective form of
bridging therapy in patients with ACLF with high MELD
scores awaiting liver transplantation and many believe that
it is a futile exercise in the absence of liver transplant [185,
186]. These results have been substantiated by the recently
published two large European randomized multicentric
controlled trials, i.e., HELIOS (for Prometheus) [177] and
RELIEF trial (for MARS) [176] which failed to show any
benefit with these modalities on short-term transplant-free
survival which was the primary end point of these studies.
The foremost reason for no demonstrable survival benefit
with the currently available artificial liver support systems
is the functional incompetence as most of these provide only
the detoxification function of the entire armamentarium of
liver functions and thus incorporation of synthetic function
by living hepatocytes, i.e., the “bioartificial liver” or therapies to potentiate hepatic regeneration look more realistic.
The other major challenge that remains is to decide the timing of therapy so as to derive maximal therapeutic benefit,
i.e., whether to consider it before or after the onset of sepsis
because by the time multi-organ failure is manifest, the benefits of intervention with these devices are not to be expected.
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In a large proportion of patients with ACLF, however,
liver transplant is not feasible, due to lack of an organ, a
donor, severity of the illness or other social challenges.
There are few alternatives at present to liver transplant.
There have been promising results of the use of growth
factors in such patients. Garg et al. [28] have shown that
granulocyte colony-stimulating factor (GCSF) can help in
hepatic regeneration by mobilizing bone marrow-derived
CD34 + cells. In addition, it significantly reduced the development of sepsis and subsequent multi-organ failure. These
data were substantiated in another study from the East in
patients with HBV-related ACLF [187–194].
However, despite the encouraging results and two randomized controlled clinical trials, it was felt that the use of
these agents should be undertaken only under protocols and
more data are required before recommending routine use of
these agents.
Recommendations
	7.3.1.	Plasma exchange appears to be a promising and
effective bridging therapy in patients with ACLF
to liver transplant or spontaneous regeneration [1,
C]
	7.3.2.	Plasma exchange can be safely undertaken in
patients with ACLF in specialized liver units [2, B].
	7.3.3.	Plasmapheresis may be considered as a specific
therapy for patients with Wilson’s disease and
patients with severe flare of autoimmune liver disease (deemed unsuitable for steroids) [2, B].
	7.3.4.	Combination of PE with therapies to potentiate
liver regeneration should be evaluated in patients
with ACLF [2, C].

Acute‑on‑chronic liver failure in children
An extensive PubMed search using keywords ‘Acute-onchronic liver failure in children; ACLF in children; Pediatric
acute-on-chronic liver failure; Pediatric ACLF’, returned
only 5 studies, from 3 Indian centers [195–199]. The data
on pediatric ACLF are limited and largely retrospective.
Pediatric ACLF, although less commonly described in the
literature, is not uncommon with a recent study demonstrating that around 14% of all CLD presented as ACLF [195].
ACLF was the first manifestation of a previously unknown
underlying CLD in 75–100% cases as reported in some studies [196–198]. The combined data from the 3 centers showed
that Wilson disease (41.2 – 45.7%) followed by autoimmune
liver disease (17.6–41.9%) are the commonest CLD presenting as ACLF followed by cryptogenic cirrhosis (3.2–41.2%)
[195–199]. The acute precipitating event was a hepatotropic
viral insult (37–94.1%) in most. Flare of autoimmune liver
disease (9.6–17%) and Wilson disease (0–27%), defined as
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ACLF in the absence of a recognizable acute event were also
reported [196, 197], although the definition used is not established. In a study, no acute hepatic event was found in 29% of
patients, a proportion of which could have been flare of Wilson disease [198]. As cholangitis is not currently accepted as
parenchymal insult, which happens to be the most important
event leading to decompensation in biliary atresia, the experts
decided to exclude biliary atresia from ACLF definition.
Only 8.7% of the pediatric ACLF cohorts were ≤ 3 years.
Metabolic liver diseases (MLD) account for majority of
CLD in this age group. On analysis of MLD data, it was
found that only 3/63 (4.8%) could fulfill the definition of
ACLF but were labeled as ALF as there is some overlap in
the 2 definitions [1, 199]. Children with MLD also failed
to fulfill the definition of ACLF as a proportion of them
either had longer jaundice to HE/ascites interval [200] or
had anicteric liver failure. The common acute precipitating
events of pediatric ACLF present less often before 5 years
of age: acute hepatitis A in 15.7% (personal communication ILBS data) & drug hepatotoxicity: 27.8% [201].
Do we need a modified definition of pediatric ACLF?
There is no separate definition of pediatric ACLF. The
major issues with the current definition in children are: (1)
clinical identification of hepatic encephalopathy is often
difficult and/or delayed specially those below 3 years of
age, (2) clinical ascites may be difficult to identify especially in younger children with organomegaly, (3) some
pediatric liver disease may present with liver failure
without jaundice. The current ACLF definition requires
jaundice to be followed by clinical ascites or HE within
4 weeks [1]. A delayed clinical identification or nonidentification of HE/ascites will lead to the patient either
being identified beyond the period of golden therapeutic
window or not even diagnosed as ACLF. To circumvent
the issue of difficult identification of HE, pediatric acute
liver failure study group has defined acute liver failure
as an INR greater than 2 regardless of the presence or
absence of clinical HE [199]. Pediatric ACLF cohort at
Institute of Liver and Biliary Sciences (ILBS) was evaluated to determine if the cutoff INR for defining ACLF can
be increased to 2 regardless of the presence or absence of
clinical HE. In the presence of HE, poor outcome was seen
in 42.9% and 56.6% of those with INR between 1.5 and 2
(18/90) and those with INR ≥ 2 (74/90), respectively. As
identification of HE is important but clinical identification
often difficult, ammonia which has good correlation with
HE [202] was evaluated as a surrogate marker. Ammonia
performed poorly for diagnosis of HE with AUROC of
0.642 and an ammonia level more than 150 ug/dl diagnosed HE with 61.3% sensitivity and 70% specificity. EEG
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is another surrogate but is difficult to perform, not easily
available and has not been standardized in children [203].
In the absence of a good surrogate, the experts agreed that
clinical HE should continue to remain part of the definition. West Haven scale is used in older children, whereas
modified HE assessment scale can be used for identifying
and grading HE in children up to 3 years of age [199].
Detection of clinical ascites is difficult or delays diagnosis.
Radiological ascites (mild to massive) from the ultrasound
report and clinical ascites from the discharge summaries
were compared in 127 children aged up to 3 years with
CLD. The sensitivity of clinical examination to detect
ascites was 71% with 29% being missed or identified later
when the ascites increased further. Hence, the experts
agreed to replace clinical ascites with clinical/radiological ascites in children.
Outcome and prognostication in pediatric ACLF
Theoretically, pediatric ACLF should have a better outcome
than adults as the 2 commonest CLD, i.e., Wilson disease
and autoimmune liver disease presenting as pediatric ACLF
have specific medical therapy, better hepatic reserve (due
to shorter duration of illness) and lesser incidence of comorbidities. Outcome has been defined at different time
points in the published pediatric literature [195–204]. Wilson disease and cryptogenic cirrhosis have poor prognosis
with 48.8% and 30% survival, respectively. Those with
acute HEV (50%), DILI (37.5%) and flare of Wilson disease (37.5%) have low survival. Half of the pediatric ACLF
have one or more organ failure, with the commonest being
cerebral and renal. Presence of ≥ 3 organ failures was associated with poor outcome. Outcome was poor in those with
AKI and grade 3–4 HE. The presence of AKI increases the
likelihood of death several folds [204]. Among the prognostic models evaluated in ACLF, APACHE-III, SOFA and
CLIF SOFA score have been described in children [196,
197]. AARC score was recently shown to have excellent
prognostic value in adult ACLF cohort [3]. Serum creatinine (SCr) value included in AARC score is unreliable as
children have lower SCr, which is further accentuated due
to malnutrition, sarcopenia and decreased endogenous production. A pediatric modification of AARC score was made
replacing the absolute SCr with grades of AKI [204]. Both
the AARC score (AUROC 0.945) and its pediatric modification (AUROC 0.951) were superior to the other prognostic
scores in pediatric ACLF cohort. A cutoff score of 11 or
more identified poor outcome with 87.5% sensitivity and
90.6% specificity. Poor outcome group showed a rise, while
the good outcome group showed decline in AARC-ACLF
score at day 4 (∆AARC-ACLF: Poor outcome: 1 ± 1.1 vs.
Good outcome: − 0.6 ± 0.9, p < 0.0005) [204].
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The proposal for a definition of ACLF in children by the
APASL is the first such attempt to address the issue of ACLF
in children. Hope this will be enriched by further large and
multicentric studies in future.
Recommendations
	8.0.	Acute-on-chronic liver failure in children.
	8.1.	Pediatric ACLF is not uncommon (1, B).
	8.2.	The most common underlying liver diseases presenting
as ACLF in children are Wilson disease and autoimmune liver disease (1, B).
	8.3.	The most common acute precipitating events are viral
(HAV, HEV, HBV) hepatitis and flare of underlying
disease/hepatotoxic drugs (1, B).
	8.4.	Standardized definitions of disease flare, as a precipitating event need to be further updated (2, C).
	8.5.	The existing definition of ACLF can be used to diagnose ACLF in children. However, there is an urgent
need to generate more multicentric data from prospective studies.
	8.6.	Clinical diagnosis of hepatic encephalopathy, though
difficult, is important for diagnosis/prognosis of pediatric ACLF. For diagnosis of HE in older children, West
Haven scale can be used. For children less than 3 years,
modified HE assessment scale can be used (2, C).
	8.7.	Clinical and/or radiological ascites can be used for
defining ACLF in children (2, B).
	8.8.	Short-term (28-day) outcome is poor in approximately
33% of pediatric ACLF subjects (2, B).
	8.9.	One or more extrahepatic organ failures are seen in
around half of children with ACLF (1, B).
	8.10.	Acute kidney injury and grade 3-4 HE are most common extrahepatic organ failures in pediatric ACLF.
	8.11.	Half the cases of ACLF at presentation have AKI. The
presence of AKI increases the risk of poor outcome by
several folds (2, B).
	8.12.	AARC-ACLF model is an easy, bedside, dynamic
prognostic model for pediatric ACLF (B, 2).
	8.13.	A score more than or equal to 11 needs urgent listing
and evaluation for liver transplant (2, B).
	8.14.	Pediatric modification of these scores may be useful
(2, C).

Conclusions
In summary, the field of ACLF has moved very rapidly in the
past 5 years. The availability of large volume of published data
from the East and the West has allowed reassessing the initial
definitions. The need for having a well-defined homogenous
population of patients, with wellcharacterized acute and chronic
insult and which would reflect the term acute-on-chronic liver
failure, is at the core. Attempts to abrogate, ameliorate or
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reverse the ongoing injury would allow return of hepatic synthetic functions and reversal of the liver damage. Early predictors of mortality and non-reversibility of the condition would
pave way to offer priority liver transplantation to such patients.
An attempt to converge the thoughts from the East and West is
possibly the only way forward to achieve more scientific and
timely interventions for such seriously sick patients.
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